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ABSTRACT 
 
DEVELOPMENT OF A MICROFLUIDIC PLATFORM FOR TRACE LIPID 
ANALYSIS 
 
 
 
By 
Andrew Davic 
May 2016 
 
Dissertation supervised by Michael Cascio 
 The field of lipidomics encompasses the study of pathways, networks, and 
functionality of cellular lipids in biological systems.  The lipid subclass, primary fatty acid 
amides, are crucial to nervous system signaling, receptor function, and numerous other 
physiological roles.  Chapter 1 details these bioactive properties of several well-studied 
primary fatty acid amides as well as their biosynthesis, degradation, and most common 
analysis techniques.  As these bioactive lipids are endogenously present in trace and ultra-
trace abundancies, the field of microfluidics presents an attractive alternative analysis 
system to incorporate minimization of sample and reagent usage, analysis cost reduction, 
highly sensitive detection pairing, and decreased analysis time, all while limiting sample 
handling.  Chapter 2 provides a microfluidics-based review of common device fabrication 
techniques, droplet microfluidics, and detection systems.   Current primary fatty acid amide 
 v 
analysis techniques have detection limits on the periphery of endogenous concentrations, 
presenting the need for a more sensitive detection system, such as fluorescence.  Chapter 
3 serves as the foundation in developing methodology to analyze these amides and their 
conjugate fluorescently-tagged primary amines.  Chapter 4 focuses on the development of 
a microfluidic platform capable of efficient on-chip fluorescent tagging reactions and the 
coupling of a highly sensitive laser induced fluorescence detection system capable of 
detection limits several orders of magnitude lower than currently employed mass 
spectrometry techniques.  In addition, the appendix details the method development for the 
quantitative analysis of the anti-inflammatory and anti-cancer drug, celecoxib, uptake into 
novel drug delivery vehicles. 
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Chapter 1 
Review of Primary Fatty Acid Amides and Lipidomics 
 
1.1. BACKGROUND AND SIGNIFICANCE 
Lipidomics is broadly defined as a comprehensive study of pathways, networks, 
and functionality of cellular lipids in biological systems.  Lipids are relatively water-
insoluble and are small, amphiphilic bioorganic molecules that have numerous biochemical 
functions and properties.  They play important roles in cell makeup, energy storage, and 
signaling, while also acting as essential hormones.  Lipids are divided into eight different 
categories, with each having several main classes and further subclasses.  The broad range 
of molecular diversity is shown in Table 1-1 with each lipid category as well as a selected 
subclass depicted.1, 2  The lipid category of fatty acyls, and more specifically its subclass, 
primary fatty acid amides (PFAMs), will be the focal point of this review.     
 
 
 
 
 
 
 
 
 
 
 2 
Lipid Category 
(Subclass) 
Common 
Example 
Structure 
Fatty Acyls 
(Fatty Amides) 
Oleamide 
 
Glycerolipids 
(Monoalkylglycerols) 
1-
Oleylglycerol 
 
Glycerophospholipids 
(Diacylglycero-
phosphoserines) 
PS 
 
Sphingolipids 
(Sphing-4-enines) 
Sphingosine 
 
Sterol Lipids 
(Cholesterol and 
Derivatives) 
Cholesterol 
 
Prenol Lipids 
(Bactoprenols) 
Decaprenol 
 
Saccharolipids 
(Pentaacyl-
aminosugars) 
Bordetella 
pertussis lipid 
A 
 
Polyketides 
(Polyenes) 
Nystatin 
 
Table 1-1.    Examples of the variety of lipid classes and example subclasses.  A representative 
molecule was chosen from each lipid subclass, with structures shown to show diversity of 
classes.1, 2 
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1.2. PRIMARY FATTY ACID AMIDES 
PFAMs, along with N-acyl amines, fatty acyl homoserine lactones, and N-acyl 
ethanolamines, are a subclass of fatty amides within the fatty acyl lipid category.1, 2  These 
bioactive lipids are important in nervous system signaling, receptor function, and numerous 
other physiological roles.  Structurally, PFAMs contain a carboxamide head group and an 
acyl tail varying in both length and unsaturation.  The high level of variation in bond length, 
unsaturation (both the number of unsaturated bonds as well as position), and the presence 
of isomers provide a great deal of biological and physiological diversity.  Endogenous fatty 
acid amides within mammalian organisms are present only in even chain lengths, typically 
ranging from 16 to 24 carbons in the aliphatic region.  Palmitamide (C16:0), 
palmitoleamide (C16:19), oleamide (C18:19-cis), elaidamide (C18:19-trans), and linoleamide 
(C18:29,12) were the first PFAMs to be identified in 1989 from luteal phase plasma.3   
 
1.2.1. Oleamide 
Oleamide is one of the most widely studied PFAMs due to its vast array of 
physiological effects and functions.  Oleamide was first characterized (along with 
erucamide [C22:113]) from the cerebrospinal fluid of sleep deprived cats.4-6  Interest in 
sleep induction research extends well back to the early 1900s with initial endogenous sleep 
inducers first realized in 1913 by Pieron et al.7  Cerebrospinal fluid (CSF) from sleep 
deprived dogs was transfused into control dogs, resulting in 6-8 hours of sleep induction.  
Conversely, control dogs receiving CSF from highly alert dogs remained awake.   
 
 4 
Modern day sleep induction research conducted by Lerner and Cravatt analyzed 
CSF in search of novel compounds that accumulated in cats during sleep deprivation.  
Preparative high performance liquid chromatography (HPLC) along with mass 
spectrometry (MS) was able to identify a major component to be oleamide.4  Originally 
referred to as cerebrodiene, oleamide was only present in trace amounts of the sleep 
deprived cats (0.1-5 pmol/100 µL) while not being detected in the control samples.5   
Unsaturated fatty acid amides have been of interest due to their potential ability to 
alter neuronal function and suppress neurotransmitter release through interactions with the 
cannabinoid receptor.8-10 Due to structural similarity to a prototypical endocannabinoid, N-
acylethanolamine anandamide, as well as common enzymatic degradation by fatty acid 
amide hydrolase, oleamide has been studied as a potential cannabinoid receptor agonist.  
Although not technically classified as an endocannabinoid, as binding to endocannabinoid 
receptors only occurs at high concentrations, oleamide displays characteristic properties 
similar to that of anandamide.  Because anandamide has vasorelaxant properties in the rat 
mesenteric arterial bed 11, oleamide was investigated for vasorelaxant properties in the 
same artery.  Oleamide was found to exhibit potent vasorelaxation via multiple 
mechanisms of agonistic receptor protein binding involving the endothelium, vascular 
smooth muscle layer, and sensory nerves.12  Such dose-dependent vasorelaxation induction 
has been found to be mediated by endothelial cannabinoid receptors, endothelial 
independent transient receptor potential cation channel subfamily V member 1, as well as 
contribution from both nitric oxide and potassium channels.13  Additional physiological 
effects of oleamide similar to that of cannabinoids are also observed in food intake and 
sexual behavior.14  Systematic injections of oleamide in rats as compared with anandamide 
 5 
injections resulted in overeating at all doses.  Conversely, all doses of anandamide had 
direct correlations to sexual behavior, whereas oleamide showed no effect, showing that 
oleamide displays some cannabinoid-like properties, however it is not actually classified 
as such.14  Oleamide induced hypnotic, analgesic, and anxiolytic effects with very low 
dependence liability, contrasted by similar effects produced from exogenous cannabinoid 
agonists that have a greater potential for inducing severe physical dependence syndromes.15  
While systematic administration of oleamide has been shown to be an effective 
sleep inducer, decreases in both body temperature and locomotor activity have also been 
observed.  Dose-dependent hypothermic responses from oleamide administration has been 
differentiated from the known relationship of the sleep-wake cycle and body temperature 
(i.e., body temperature being at its highest during wakefulness and a gradual decrease 
during sleep, with the lowest temperature typically observed during rapid eye movement 
sleep 16, 17), suggesting the mechanisms related to oleamide effects on body temperature 
and sleep induction differ.14  Although the specific mechanism behind hypothermia 
induction is unknown, a possibility is the ability of oleamide to potentiate both type-A ɣ-
aminobutyric acid receptors (GABAAR) and subtype 1A 5-hydroxytryptamine (serotonin) 
receptors (5-HT1A).  This hypothesis stems from findings that systematic activation of both 
GABAA and 5-HT1A receptors induce hypothermia in rats.
18-20  As a possible consequence 
of oleamide’s hypothermic effects, intraperitoneal oleamide injections have also produced 
low motility.14  The induction of sleep, hypothermia, and hypomotility caused by 
administration of oleamide is not mediated by changes in blood pressure and/or heart 
rate.14, 21 
 6 
Oleamide is an endogenous brain lipid in mammals, inclusive of humans.  It is 
highly selective in potentiating serotonin (5-HT1A ,2A, 2C) and GABAA receptors, producing 
long-lasting inhibition of receptor function, and thereby affecting alertness, sleep, and 
mood.22-25  Although several naturally occurring fatty acids (e.g., oleamide, 
arachidonamide, anandamide, oleyl ethanolamide) have been shown to potentiate the 5-
HT2A receptor, oleamide is the most effective, likely due to the presence, position, and 
stereochemistry of the Δ9-cis double bond (subtle structural variations reduce/eliminate 
activity).23  Oleamide also potentiates the metabotropic 5HT7 receptor via an allosteric site.  
Potentiation of this G protein coupled receptor influences G protein signaling, thereby 
potentially influencing behavioral responses.23   It has also proven to be effective at 
blocking gap junction communication between rat glial cells, while not effecting 
intercellular calcium signaling.26, 27   
In addition to its vast array of physiological properties, oleamide has recently been 
shown to provide potential environmental benefits, specifically as an algicide in controlling 
toxic cyanobacterial blooms.28-30  Amine derivatives of fatty acids, which are a main 
constituent of plasma membranes and thylakoids, display stronger antimicrobial effects 
than their corresponding free fatty acids, with oleamide reported to have inhibitory effects 
against pathogenic bacteria.28-30  Sewage effluent and agricultural run-off results in 
excessive nitrogen and phosphorus accumulation in water, resulting in hepatotoxic 
microcystins-producing cyanobacterial blooms, posing a high health risk to human 
populations.31  Oleamide has been determined to have an EC50 of 8.60 ± 1.20 mg/L on the 
growth of Microcystis aeruginosa, presenting an easily obtained and biodegradable 
solution for bloom-forming cyanobacterial control in water supplies.32 
 7 
1.2.2. Erucamide 
 Erucamide (C22:113) was first isolated and purified in 1990 from bovine omentum.  
It was found to be the major bovine mesentery angiogenic lipid with activity assessed by 
chorioallantoic membrane assay with as little as two micrograms of lipid.33  Angiogenic 
activity was also found to occur with rat corneal micropocket and mouse dorsal air-sac 
assays.  Mitchell et al. showed further dose-dependent angiogenic properties with 
implantation of microgram quantities of erucamide into injured skeletal muscle.  This 
resulted in an increased amount of large diameter blood vessel formation, particularly 
around the implant site.  Conversely, higher doses of erucamide have shown fewer large 
diameter blood vessel formations, potentially due to a toxic effect of erucamide at high 
doses.34    Erucamide also modulates water balance.  Hamberger and co-workers reported 
the isolation of a previously unidentified inhibitor of induced diarrhea from big blood 
plasma to be erucamide.35  An administered dose of 50 pmol/kg body weight 
(approximately 50 pM) of erucamide gave maximal inhibition of cholera toxin-induced 
intestinal fluid hypersecretion, as compared with 8.6 nM erucamide found endogenously.35  
Although this dose only represents a marginal increase in erucamide concentration once 
distributed throughout the body, initial concentrations may be very high in the blood.  
Erucamide has also been found in the brain, cerebral spinal fluid, lungs, liver, and 
intestines.35  The mechanisms of action for erucamide’s angiogenic and anti-diarrheal 
activities, however, remain to be determined.   In addition to its physiological properties, 
erucamide is also used, along with oleamide and stearamide, as additives in plastics, 
textiles, rubber, and lubricant oils.36  
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1.2.3. Linoleamide 
 Linoleamide (C18:29,12) is another endogenous PFAM that has been found to 
induce sleep in cats, rats, and humans.4  Also similar to oleamide, linoleamide was 
enzymatically synthesized in the brains of stimulated rats.37  Huang and co-workers were 
the first to examine the effects of linoleamide on isolated cells by measuring changes in 
calcium ion concentration in Madin-Darby canine kidney epithelial tubular cells.  
Linoleamide was reported to induce intracellular calcium ion concentration increases with 
an EC50 of 20 µM.  It is believed that this occurs by the release of internal Ca
2+ from the 
endoplasmic reticulum.38  Linoleamide and its metabolites have been found in the urine of 
rats dosed with linoleamide, suggesting that it may also play a role in activating ion 
transport in renal cells.39  Prolonged elevations in Ca2+ concentrations have led to cell 
injury and apoptosis, suggesting the possibility that linoleamide may be nephrotoxic.40 
 
1.3. PRIMARY FATTY ACID AMIDE BIOSYNTHESIS AND DEGRADATION 
 
1.3.1. PAM Amidation 
 The biosynthesis, metabolism, and degradation properties of PFAMs have been a 
topic of interest to lipidomic researchers since the discovery of the physiological properties 
exhibited by endogenous oleamide.  Divito and Cascio have compiled an extensive review 
outlining the progress that has been made in this field, while also highlighting PFAM 
physiology, receptor protein interactions, and current methods of analyses.41  The enzyme, 
peptidylglycine α-amidating monooxygenase (PAM), found in both the plasma and CSF 
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of mammals, is known to convert peptidyl glycines to their respective amide form and has 
a preference for hydrophobic peptide substrates.42-45   
The first reported naturally occurring non-peptide substrate for PAM was N-
myristoylglycine.  PAM catalyzes the oxidative cleavage of N-fatty acylglycines into 
PFAMs (and in this case, into myristamide), thus, proposing a catabolic pathway for the 
biosynthesis of PFAMS.46  Consistent with the finding that N-myristoylglycine acts as a 
substrate for PAM is that the enzyme shows a preference in amidating glycine-extended 
peptide substrates having a hydrophobic amino acid at the penultimate position.42 This 
suggests that the majority of N-fatty acylglycines will act as PAM substrates, and this has 
been proven with fatty glycines ranging from formylglycine through linoleoylglycine being 
amidated by purified recombinant type A rat PAM and verified by nuclear magnetic 
resonance (NMR) spectroscopy.47  These studies determined that the fatty glycines go 
through an intermediate form, identified as N-acyl-α-hydroxyglycine, prior to oxidative 
cleavage by peptidyl-α-hydroxyglycine α-amidating lysase (PAL).47   
Carpenter et al. analyzed PAM assays by HPLC showing the reactants, 
intermediates, and products for N-octanoylglycine and N-lauroylglycine (C8 and C12, 
respectively).48  HPLC chromatograms compared the relative abundance of all components 
during the PAM enzymatic conversion of N-acylglycines to amides both in the presence 
and absence of Ac-Phe-pyruvate, a PAL inhibitor.  Without the inhibitor added, the 
conjugate amides increased in abundance as both the fatty glycine and the intermediate α-
hydroxyglycine decreased relative to their abundance with the inhibitor added.48  Similarly, 
overexpression of PAM in N18TG2 mouse neuroblastoma cells resulted in an increased flux 
of oleic acid to oleamide, while inhibition of PAM resulted in an accumulation of N-
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oleoylglycine, which was subsequently metabolized to oleamide.46, 47, 49  This was the first 
report of N-oleoylglycine from a biological system, and a three-step catabolic pathway was 
proposed for the biosynthesis of a PFAM beginning with the free fatty acid being converted 
into acyl-Coenzyme A (CoA), acyl-CoA converted into N-acylglycine, and finally N-
acylglycine converted into a PFAM.46, 47, 49 
Cytochrome c has been discovered as an oleamide synthase from high percentage 
ammonium sulfate fractions of rat liver and kidney extract incubated with a radiolabeled 
acyl-CoA.50  Driscoll et al. were the first to report the ability of cytochrome c to catalyze 
the biosynthesis of oleamide from oleyl-CoA.  The enzyme catalyzes the formation of acyl-
glycine from acyl-CoA and glycine in the presence of ammonium ion and is significantly 
enhanced by hydrogen peroxide.  The activity was found to be stable to both heat 
denaturation as well as limited exposure to proteolytic enzymes.  The activity was found 
to display physiological temperature and pH, and was positively identified as cytochrome 
c by proteomic, biochemical, and immunologic analyses.50  These findings raise the 
possibility that PFAMs may be physiologically synthesized by a second or alternative 
mechanism of cytochrome c catabolism.  In addition, it has been found that cytochrome c 
will catalyze formation of selected long chain fatty acyl amino acids.  Mueller and Driscoll 
documented the successful catalytic formation of oleoylglycine from oleyl-CoA, glycine, 
and hydrogen peroxide as reactants.51  It appears likely that cytochrome c and PAM work 
together, with cytochrome c producing acylglycine from acyl-CoA, and PAM converting 
the acylglycine to the conjugate PFAM.   
In addition to catalyzing the biosynthesis of PFAMs, cytochrome c exhibits the 
potential ability of generating a broad range of lipid signaling molecules and precursor 
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substrates for numerous other bioactive enzymes.  The catalysis of bioactive messenger 
lipids by cytochrome c shows possible relevance to apoptosis as oleamide has been shown 
to inhibit gap junction communication.51  It is plausible that the failure in the biosynthesis 
of oleamide by cytochrome c may result in the spread of apoptosis via open gap junctions 
across healthy networks of cells, also known as bystander killing.26, 27  Immunoreactive 
cytochrome c has been found concentrated in secretory granules which contain PAM.52, 53  
This localization suggests cytochrome c may play a role in intercellular communication, as 
the generation of oleoylglycine could be accomplished for the purpose of regulated 
secretion.  Cytochrome c has also shown to catalyze the biosynthesis reaction with oleoyl-
CoA using select amino acid substrates other than glycine as well as using other primary 
amines or long chain fatty acyl-CoA compounds as substrates.51, 54   
 
1.3.2. Primary Fatty Acid Amide Degradation 
 Fatty acid amide hydrolase (FAAH), a member of the amidase signature family, is 
a 65 kDa integral membrane enzyme consisting of a single N-terminal transmembrane 
domain.  FAAH is one of the most highly characterized enzymes involved in the hydrolysis 
of bioactive lipids, inclusive of PFAMs.  A prominent role of FAAH involves the 
termination of the signaling of endocannabinoids and oleamide in the central nervous 
system.55  FAAH was first reported in 1993 by Deutsch and Chin as anandamide amidase, 
which was capable of the hydrolysis of anandamide.56  This enzyme was found in several 
tissues, including liver and brain, and inhibited by phenylmethylsulfonyl fluoride, a serine 
protease inhibitor.56  Cloning of FAAH by Cravatt et al. in 1996 verified that FAAH exists 
as a single enzyme and that signal termination does not involve independent or combined 
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action of several different enzymes working together.57  Transfection into COS-7 cells 
showed high enzymatic activity in the membrane fraction of these cells.   FAAH converted 
oleamide to oleic acid, but also converted anandamide to arachidonic acid, indicating that 
this enzyme can serve as a general inactivating enzyme for numerous PFAMs.57  FAAH 
differs from other members of the amidase signature family of enzymes in that it is an 
integral membrane enzyme, consisting of an N-terminal transmembrane domain that was 
not present in related familial enzymes, suggesting a straightforward mechanism for 
membrane binding.  Deletion of the first 30 amino acids produced active membrane-bound 
enzyme, signifying the likelihood of multiple pathways for membrane integration.58 
 
1.4. ANALYSIS TECHNIQUES 
 
1.4.1. Extraction and Isolation 
Sample preparation of PFAMs often involves either extraction from biological 
tissue or isolation from similar fatty acyl lipid subclasses.  The most well-known method 
of total lipid extraction from biological tissue involves the use of the Folch-Pi extraction.59  
Originally used to prepare and purify brain lipids, the Folch-Pi extraction involves a two-
step process.  The first step requires tissue to be homogenized in 2:1 chloroform:methanol 
(v/v) at 20-fold the volume of tissue and the homogenate is filtered.  Next, the total lipid-
containing filtrate is added to 0.2-fold water, with the lower-phase containing the total pure 
lipid extract.59  Aqueous washing of the lipid-containing organic layer has been shown to 
remove essentially all of the non-lipid contaminants with minimal tissue-lipid loss.  
Following the Folch-Pi extraction, isolation of the desired fatty acyl lipid subclass can be 
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achieved using solid phase extraction (SPE).60, 61  PFAMs were isolated from the total lipid 
extract from N18TG2 mouse neuroblastoma cells using a Discovery (DSC)-Si SPE column.  
With the total lipid extract loaded onto the column, a series of increasingly polar elution 
steps followed, with the final fraction being found to contain PFAMs, monoacylglycerols 
(MAGs), N-acyl glycines (NAGs), and N-acyl ethanolamines (NAEs).  This fraction was 
subjected to a second iteration of SPE using a DSC-NH2 column.  Another series of elution 
steps proceeded, with PFAMs being isolated to a fraction containing 3% 2-propanol in 
chloroform.  Percent recoveries of PFAMs by this SPE method were found to be greater 
than 80% from 0.5 to 20 µg with 0.5 µg being the lowest possible mass to be reliably loaded 
and isolated.61  SPE lipid fractions can be quickly analyzed by thin-layer chromatography 
(TLC) with a three-stage development procedure.  When separating lipid classes using 
TLC, visualization occurs by staining the plates with a primuline solution, which non-
covalently binds to the lipids, and becomes visible under ultraviolet (UV) radiation.61 
  
1.4.2. High Performance Liquid Chromatography 
Individual PFAMs can be chromatographically separated from one another via 
liquid and gas chromatography.  When dealing with fully saturated PFAMs, a reverse phase 
HPLC column will follow an elution order relative to acyl chain length, with the shortest 
chain PFAM eluting first.  PFAM separation usually requires the use of a C18 stationary 
phase column, however, slightly more polar C8 columns can also be used when the acyl 
chain is twelve or less carbons in length.48  Points of unsaturation in the PFAM (double 
bonds) result in an earlier elution than its corresponding fully saturated analog.  Isocratic 
elution may be sufficient when separating a mixture of fully saturated PFAMs, however, 
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for more complex mixtures including PFAMs with one or more points of unsaturation, a 
gradient elution profile must be developed with a mobile phase consisting of water and 
either acetonitrile or methanol.  The term “critical pair” results from a certain PFAM 
containing one double bond having approximately the same retention as a fully saturated 
PFAM containing an acyl chain of two fewer carbon atoms.  Due to the highly nonpolar 
acyl chain, PFAMs do not retain well using normal phase chromatography, however, this 
technique can be applied to separating classes of polar neutral lipids from a total lipid 
extract.  Normal phase chromatography can successfully isolate fatty acyls, 
triacylglycerols, diacylglycerols, MAGs, NAGs, PFAMs, and NAEs.  Although a common 
theme amongst polar neutral lipids are varying length acyl chains, the differences in head 
group polarity allow for normal phase separation.  This same principle has also been 
applied to the separation of lipid classes using TLC.61  
  
1.4.3. Gas Chromatography 
 Gas chromatography (GC) can also be used to separate either derivatized or 
underivatized PFAMs.  The most common technique of PFAM derivatization involved the 
use of bis-trimethylsilyltrifluoroacetamide in toluene.  This produced the highest signal to 
noise ratios (S/N) when paired with ion trap mass spectrometry.62  Detection limits 
approached the low picomol range with the use of selected ion monitoring (SIM).  Further 
work involved exploring derivatization techniques with a series of unsaturated PFAMs, 
however, derivatization lacked adequate efficiency at low concentrations.61  Underivatized 
PFAM analysis by GC/MS is successful in separating a series of saturated PFAMs as well 
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as PFAMs with varying points of unsaturation, however this technique falls short with its 
inability to distinguish by bond position due to the lack of column selectivity.61 
 
1.4.4. Detection Techniques 
 Detection of PFAMs is of particular importance as the technique must allow for 
sensitivity encompassing and surpassing the trace and ultra-trace abundance of these 
biological molecules.  Arguably the most commonly used detection technique for HPLC is 
Ultraviolet-Visible (UV-Vis) spectroscopy.  HPLC-UV-Vis detection at 210 nm (PFAMs) 
and 214 nm (NAGs) was used in developing a method to evaluate the PAM-mediated 
enzymatic conversion of NAGs to PFAMs by separating a series of PFAMs (C2-C22) and 
NAGs (C2-C12).  UV-Vis detection resulted in detection limits estimated to be 
approximately 100 µM (1 nmol), which proved adequate for kinetic assays of PAM under 
physiological conditions.48   
The use of MS can complement both GC and HPLC techniques.  PFAM separation 
using GC is typically detected using a mass selective detector.  As previously 
mentioned, mass detection limits using an ion trap MS can approach low-picomole 
detection limits, however, derivatization techniques can be time and sample consuming 
and column selectivity can present separation problems.61-63  A soft-ionization mass 
spectrometry technique, atmospheric pressure chemical ionization (APCI), was used with 
HPLC to detect PFAMs in tallow with detection limits reaching the low femtomol range.64  
Depending on the type of MS, SIM or multiple reaction monitoring (MRM) can be utilized 
to lower detection limits, allowing for trace analysis.  Hard ionization sources such as 
electron impact (EI) ionization with GC allows for the nearly complete fragmentation of 
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the molecular ion.  The resulting characteristic fragmentation patterns can be used to 
elucidate structural information or compared with fragmentation databases for component 
identification, when applicable.  Tandem mass spectrometry (MS-MS) enabled the 
collection of collision induced dissociation (CID) patterns of saturated and unsaturated 
PFAMs using a quadrupole time of flight MS with electrospray ionization (ESI).  CID 
resulted in characteristic spectra that were used to propose fragmentation mechanisms, 
which were able to differentiate saturated versus unsaturated PFAMs quickly and 
accurately.65  Additional tandem MS quantitation of NAGs in Sprague-Dawley rat brain 
showed quantitation limits in the picomole (6-895 pmol) range per gram of tissue using 
HPLC-MS-MS with a triple quadrupole (QqQ) detector in MRM mode.66 
As trace and ultra-trace detection methods are required for endogenous PFAM 
analysis and quantitation, fluorescence spectroscopy yields the potential of single-molecule 
detection limits when utilizing fluorophores with high quantum yields.67-71  Analytes such 
as PFAMs do not contain conjugated π-bonding systems capable of native fluorescence, 
therefore they must be derivatized, or fluorescently tagged, with an appropriate 
fluorophore, with the resulting fluorescence response directly proportional to analyte 
concentration.  Furthermore, the growing trend of lower detection limits coinciding with 
“green” chemistry has popularized microfluidics with the capabilities of providing a total 
analysis system with “lab on a chip” technologies.  The coupling of microfluidics with laser 
induced fluorescence (LIF) has the potential of being the most sensitive detection system 
to date for analysis of PFAMs and is further discussed in the subsequent chapters.   
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1.5. SUMMARY 
Fatty acyls comprise a highly studied class of lipidomics focused largely on 
signaling.  Of this specific class, a wide range of primary fatty acid amides have been found 
to be endogenously present and display a gamut of physiological properties.  Oleamide is 
perhaps the most studied with initial research near the turn of the twentieth century linking 
it to sleep deprivation.  Additional properties show similarities to the endocannabinoid, 
anandamide, resulting in the likelihood of oleamide acting as a cannabinoid receptor 
agonist.  Oleamide also displays vasorelaxant, hypnotic, analgesic, and anxiolytic effects, 
stimulates overeating, and blocks gap junction signaling, amongst numerous others.  
Erucamide, like oleamide, has shown effects relating to sleep induction and angiogenesis 
as well as being used as additives in various synthetic materials.  Erucamide has been found 
in several bodily organs and shown to modulate water balance.  Linoleamide has been 
shown to increase calcium ion concentrations and activate ion transport in renal cells, albeit 
displaying potential nephrotoxicity. 
 The biosynthesis of PFAMs centers on PAM, the enzyme known to convert 
peptidyl glycines to their respective amide form via post-translational modification.  
Working harmoniously with PAM, cytochrome c catalyzes the synthesis pathway from 
acyl-CoA to the acyl-glycine form in the presence of ammonium ion, while PAM then 
converts the acyl-glycine to its conjugate PFAM form.  The enzyme FAAH is responsible 
for the degradation of PFAMs by hydrolyzing the bioactive lipids.  FAAH is also involved 
in the termination of the signaling of endocannabinoids and oleamide in the central nervous 
system.   
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 PFAMs can be extracted from biological tissue using a Folch-Pi extraction 
technique where the analyte is solubilized in an appropriate solvent prior to a liquid-liquid 
extraction.  Purification using solid phase extraction is followed prior to highly sensitive 
analysis and detection techniques.  Both gas and liquid chromatography are often used to 
separate mixtures of PFAMs.  Normal-phase liquid chromatography is suitable to separate 
out entire lipid classes, whereas reversed-phase liquid chromatography is used to separate 
out mixtures of lipids within a class.  Direct detection of PFAMs can be accomplished 
using a mass selective detector, however, conversion to their conjugate amine form and 
subsequent fluorescent tagging provides the greatest sensitivity with a suitable 
fluorescence-based detector. 
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Chapter 2 
REVIEW OF MICROFLUIDICS 
 
2.1. BACKGROUND AND SIGNIFICANCE 
 The concept of microfluidics is broadly defined as a system that either processes or 
manipulates small volumes (10-9 to 10-18 liters) of fluids within channels on the micrometer 
scale.  Microfluidics presents a gamut of useful capabilities inclusive of the minimization 
of sample and reagent usage, analysis cost reduction, specificity of device design, high 
resolution chromatographic separations, highly sensitive detection pairing, and decreased 
analysis times.  Several recently published reviews expand upon these capabilities and 
present new and innovative applications of this growing field.72-75  Various fabrication 
techniques exist, which can all be performed relatively inexpensively, as well as in-
house.76-85  A few of the more common materials used in microfluidic device fabrication 
are polymer based with polydimethyl siloxane (PDMS), glass, thermoplastic, paper, and 
silicon.79, 86-88  The actual technique of fabrication can vary widely based on materials used 
and application, however, the most common consist of soft lithography, wet etching, 
microcontact printing, and substrate bonding.  
 Another advantage of microfluidics is the ability to achieve a “Lab on a Chip”, 
otherwise known as a micro total analysis system (µTAS).  A true µTAS begins with the 
introduction of the fluidic sample or analyte, followed by reaction, separation, or isolation 
steps, and finally an applicable detection method.  The introduction of sample or analyte 
into a microfluidic system is often accomplished by pressure driven flow.  Once within 
microchannels, the fluidic flow is intrinsically laminar in nature, with the sole form of 
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mixing being simple diffusion between and within fluidic layers.89  In order to accomplish 
efficient mixing and reactions on-chip, some form of channel manipulation must be made 
to reorient the flow path.90, 91  Reaction efficiency may also be  increased by the production 
of droplets within the flow.92  Separation of analytes within a mixture can be achieved 
within a microfluidic device via the introduction of stationary phase packing material.93  
The packing material can be incorporated into the device and held in place using frits or 
fritless weirs designed into the device fabrication procedure.  Finally, several detection 
systems can be seamlessly implemented with the use of a microfluidic device such as 
spectroscopic, fluorescence, or mass selective techniques.94-99  In this chapter, we review 
common device substrates and fabrication techniques, droplet formation and manipulation, 
and microfluidic detection systems. 
 
2.2. MICROFLUIDIC DEVICE FABRICATION TECHNIQUES 
 
2.2.1. Polymer Based Devices 
 Of all the materials used for fabrication of microfluidic devices, the most commonly 
used are those consisting of polymers or elastomers.  Elastomeric microfluidic devices 
share common advantages over more traditional substrates (glass- and silicon-based 
devices) such as reduced fabrication cost, simplified manufacturing procedures, and a wide 
range of available polymeric materials.100  Some of the various polymers used include 
PDMS, polystyrene, polypropylene, polyvinylcarbonate, polycarbonate, and polymethyl 
methacrylate.  PDMS is the most commonly used polymer for microfluidic device 
fabrication due to many advantageous attributes, inclusive of its elastomeric properties, 
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biocompatibility, gas permeability, optical transparency, ease of molding sub-micron 
features, ease of self-bonding and glass-bonding, high chemical inertness, and low 
manufacturing costs.86, 87   
Initial fabrication of polymer based microfluidic devices is usually achieved via 
photolithography.  Photolithographic fabrication of polymeric material is easier, more 
flexible, and more cost-effective than fabrication techniques used for devices comprised of 
glass or silicon.  Also, the ease of polymeric device fabrication allows for usefulness in 
quick development of prototypical devices.  The process of photolithographic fabrication 
of a PDMS microfluidic device is described in detail by McDonald and Whitesides.76  The 
first step in photolithographic fabrication requires the production of a master mold.  This 
starts with the design of a photomask that contains the networks of channels and various 
spatial features required.  The photomask can either be machine-fabricated with metallic 
coatings or designed and printed in-house with computer drawing software packages and 
a high resolution printer.78  Metallic photomasks, often consisting of chrome, can achieve 
spatial resolution as low as three micrometers, while lower-cost, high-resolution printed 
transparencies is often twenty micrometers or greater.  A clean silicon wafer is coated with 
an epoxy-based negative photoresist to the desired thickness.  The photoresist is important 
in defining channel depth profiles in the finished device.  A pre-fabricated photomask is 
placed over the resist, and irradiated using a high power UV lamp, causing the exposed 
channel regions of the resist to crosslink.  The exposed resist-coated wafer is developed in 
solvent that washes away the non-crosslinked region, leaving behind the master mold that 
can be used indefinitely.   
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PDMS is often supplied as two independent components, a base and a curing agent.  
When mixed at an optimal 10:1 (v/v) base:curing agent ratio, silicon hydride from the 
curing agent reacts with the vinyl groups present in the base to form a cross-linked, 
elastomeric solid.  The liquid pre-polymer is poured over the master, cured, and then easily 
removed without damaging the master due to the low surface free energy and elasticity of 
the PDMS.76  PDMS has the ability to seal to either itself or to other surfaces, reversibly or 
irreversibly, without damaging or distorting channel features.78, 101  For devices not 
designed to incorporate pressure-driven flow, PDMS provides a reversible seal by van der 
Waals contact that is watertight up to 5 psi.101  Additional pressure resistance can be added 
to reversibly-sealed devices with the use of adhesive tapes.77  Irreversible seals are often 
formed by exposure of the PDMS and the surface to which it will be sealed to air plasma, 
which serves multiple purposes.  The plasma effectively cleans any organic contaminants 
on the surfaces and generates silanol groups by oxidation of methyl groups on the surface 
of PDMS.  Plasma treatment allows for PDMS to seal to a multitude of components, such 
as glass, silicon, polystyrene, polyethylene, silicon nitride, or itself.102  Quick contact of 
the two surfaces must be made for a strong seal to occur as the oxidized PDMS surface 
will begin to reconstruct in the presence of air within a minute.103  
 
2.2.2. Paper Based Devices 
 Increasingly recognized as a low-cost, portable, disposable, and user-friendly 
microfluidic substrate, microfluidic paper-based analytical devices (µPADs) provide 
alternative technologies for diagnostic tools and point of care testing.  These devices are 
often found to be useful with disease screening in developing countries with minimal 
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infrastructure and/or limited trained health care professionals.80  µPADs were first 
introduced in 2007 by Martinez et al. by patterning paper to create millimeter-sized 
channels.79  These devices can be used with miniaturized equipment to perform diverse 
functions, such as fluidic handling and quantitative analysis on the micro-scale, rendering 
them useful as a multiplexable point of care testing platform for use in pharmaceuticals 
and healthcare, as well as applications within environmental monitoring.104-106   
Depending on desired complexity and diagnostic applications, numerous two and 
three-dimensional fabrication techniques exist for producing paper-based devices.  Two-
dimensional fabrication techniques consist of direct printing (wax, inkjet, flexographic, 
screen, and wax-screen), photolithography, plasma and laser treatment, and wet etching.  
Many of these methods can also be similarly applied to fabrication of microfluidic devices 
consisting of various other substrates.  These techniques primarily function by treatment 
of paper to convert hydrophilic sections of the paper to become hydrophobic, creating 
fluidic channels.80  The simplest, cheapest, and fastest two dimensional fabrication 
technique involves wax printing.  Cai et al. describes the wax printing fabrication process, 
using only filter paper, a wax pencil, and an oven.107  Fluidic channels were drawn by hand 
with the wax pencil onto the filter paper using a template.  The patterned paper was then 
briefly baked in an oven, causing the wax to melt and penetrate through the paper, forming 
hydrophobic walls, able to completely contain the liquid within.  This device was able to 
perform a simple colorimetric assay capable of quantitatively analyzing amino acid content 
with a tea sample.107  The simplistic nature of wax-printed microfluidic devices also proves 
useful as a µPAD prototype for implementation of inexpensive bioassays.108  To fully 
automate the application of wax to the hydrophilic paper, a wax printer can be used.81  
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Inkjet printing can be used to automate the hydrophobic fluid containment channels, 
resulting in higher precision microfluidic patterns.  This can also be used as a precise 
deposition source of biomolecules and indicator reagents, creating complete high-volume 
biochemical sensing devices at low-cost.109  Photolithographic fabrication techniques 
pattern hydrophilic zones, or channels, bound by a hydrophobic polymer.  Martinez et al. 
describes the photolithography process for fabricating a simple paper microfluidic device 
used for colorimetric glucose and protein assays in urine.79 Briefly, chromatography paper 
was soaked in an epoxy-based photoresist, spin coated, baked, and exposed to UV radiation 
through a photo-mask.  Exposed portions of the photoresist were then cross-linked, and the 
unpolymerized region removed with propylene glycol monomethyl ether acetate before 
oxygen plasma cleaning to increase hydrophilicity.  Clinically relevant ranges of glucose 
and bovine serum albumin were detected at comparable to or lower than detection limits 
for commercially-available colorimetric test strips.79   
Plasma treatment fabrication involves salinization of the paper using 
octadecyltrichlorosilane (OTS), or alkyl ketene dimer to render it hydrophobic, followed 
by plasma treatment using a mask containing channel features.  The plasma degrades the 
hydrophobic OTS-cellulose fiber bond, rendering the exposed region hydrophilic.  A 
caveat of plasma treatment, however, results from the long mean free paths in the energetic 
particles found in the plasma, causing over-etching of the substrate underneath the mask, 
thus resulting in the desired pattern to be larger than the mask.  The degradation of OTS, 
and thereby degree of hydrophilicity and extent of over-etching, can be precisely controlled 
based on the length of exposure time.  Plasma treated devices can be advantageous in that 
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functional elements such as switches, filters, and separators can be easily incorporated into 
the microfluidic system.110, 111   
Laser-treatment fabrication uses polymerization of a photopolymer to produce 
desired fluidic channels or containment wells within the paper.  This fabrication technique 
has produced leak-proof hydrophobic barriers as small as 120 µm and fluidic channels as 
small as 80 µm, which is the smallest reported paper-based fluidic pattern.112  The surface 
structure of devices using paper with a hydrophobic surface coating, such as wax paper, 
can be selectively modified and rendered hydrophilic using a CO2 laser.  The modified 
surface was shown to be highly porous, which helped to trap or localize chemical and 
biological aqueous reagents for analysis.113   
A novel, simple, and cost-effective approach for µPAD fabrication involves 
selective wet etching of hydrophobic filter paper by a paper mask.  Ordinary hydrophilic 
filter paper was made highly hydrophobic using 2% trimethoxyoctadecylsilane.  The paper 
mask, containing specific channel design features, was soaked in a sodium hydroxide 
solution and aligned onto the filter paper.  The sodium hydroxide etching agent in the mask 
selectively etched the hydrophilic channel design into the filter paper, allowing for rapid 
fabrication within five minutes.114  Renault et al. demonstrated that simple and inexpensive 
carbon electrodes can be used as bipolar electrodes (BPEs) and screen printed onto standard 
µPADs.115  Electrode patterns were photolithographically created onto a mesh using a 
screen printing kit, and the carbon electrodes were strategically screen printed onto µPAD 
using the patterned mesh as a mask.  Two driving electrodes connected to a power supply 
were sufficient to produce electrogenerated chemiluminescence on a µPAD containing an 
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array of 18 BPEs, showing the potential of conducting highly multiplexed electrochemical 
measurements on simple paper microfluidic devices.115 
 
2.2.3. Glass Based Devices 
 As micro- and nanofluidic technology continues to evolve, the applications have 
expanded along with the vast array of materials and processes for fabrication of such 
devices.  Glass based devices were of the earliest microfluidic devices developed with 
processes derived from semiconductor and microelectromechanical systems 
manufacturing. 82-84  Although PDMS-type elastomers are primarily used as microfluidic 
device substrates due their ease, quick, and low-cost manufacturing processes, many 
applications exist where glass remains advantageous.85  Microfluidic applications that 
demand high temperature resilience, high aspect ratio structures, integration of electrodes 
or electronic circuits, or precise definition of nano-scale channels still routinely demand 
the use of silicon- or glass-based devices.85, 116, 117 
 The most common form of glass microfluidic chip fabrication is bulk 
micromachining, where channel features are selectively removed from a silicon/glass wafer 
and channel encapsulation occurs by bonding the chip to a second wafer.  Glass patterning 
is completed using either wet or dry etching.  Wet etching occurs by a process initially 
similar to that of photolithography, where a glass wafer is spin-coated with a chrome layer 
followed by a photoresist later.  The wafer is exposed to UV light through a photomask, 
and the exposed regions of the photoresist, followed by the exposed chrome, are 
sequentially removed by separate chemical treatments.  The exposed glass is wet etched in 
an isotropic fashion typically using a hydrofluoric acid (HF) solution.  Once the desired 
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degree of etching is achieved, the remaining photoresist and chrome layers are washed 
away.118  It is desirable to use glass with low content of oxides such as CaO, MgO, and 
Al2O3 as these oxides result in insoluble products following the HF etching reaction.
88   
The etch rate is largely dependent on the composition of the glass, but can be 
increased by raising solution temperature or incorporating ultrasonic agitation, and reduced 
by diluting the HF solution.119  Using a 49% HF solution, Corning 7740 glass has an etch 
rate of 8 µm/min, while quartz has an etch rate of 1.3 µm/min under the same conditions.120  
Dry etching of glass is a much more tedious and less reproducible process than that of wet 
etching, and thus is typically only used when an anisotropic etching profile is desired on a 
glass substrate.  Common dry etching rates are approximately 0.5 µm/min and usually 
performed by a plasma etch in an inductively coupled plasma reactive ion etching reactor 
(ICP-RIE) 85  High temperatures resulting from the large energy transfer can cause glass 
wafers to fracture, therefore, care must be taken to precisely control temperature gradients.  
Gas precursors used for plasma etching can be SF6, C4F8, CF4, or CHF3 and a thick masking 
layer of electroplated Ni, silicon, or SU-8 photoresist is required due to the relatively low 
selectivity of the etching process.121, 122 
 Direct bonding of glass microfluidic chips to another glass surface is required to 
provide enclosed fluidic channels within the device.  Simple van der Waals force keeps 
two clean, flat glass surfaces in-tact with a bond strength of only 0.6 MPa.123  As glass 
begins to soften at high temperatures, fusion bonding of glass microchips can occur at a 
temperature of 650°C using an annealing furnace.  Care must be taken to gradually cool 
the glass after annealing to prevent breakage.124   Fusion bonding can be combined with 
glass surface activation from a calcium solution or nitrogen radical activation by a 
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microwave reactor following an oxygen RIE treatment.125  Using the latter glass 
pretreatment followed by 600°C annealing temperature, bond strengths of up to 24 MPa 
were achieved.  
 
2.3.1 DROPET-BASED MICROFLUIDICS 
The trend of miniaturization has enabled important technological advancement in 
recent decades in fields such as electronics, with transistors per integrated circuit roughly 
doubling every year since their invention in 1961, however, this trend in chemistry and 
biology has been pronouncedly less dramatic.126  Miniaturization of reaction volumes has 
been reduced only about 1,000 fold over this time, from milliliter volumes in test tubes to 
microliter volumes in microliter plates.  Intrinsic problems in miniaturizing reaction 
volumes lie in evaporation rates and capillary action.127, 128  The use of microfluidic devices 
have the potential to overcome these issues by droplet technology, which first came to 
realization in 2001 when mono-disperse droplets were formed within polyurethane 
microfluidic chips.129  Droplet-based microfluidics is a subcategory of microfluidics built 
around the premise of creating discrete volumes of fluid using immiscible phases.  More 
traditional microfluidic systems incorporate continuous and laminar flow profiles, 
however, droplet microfluidics provide an alternative to continuous flow with a solution to 
overcome the challenges of laminar flow.130   
Droplets in microfluidics essentially serve as transport and reaction vessels, and are 
selectively introduced in pico- to nanoliter volumes at high throughput within encapsulated 
channels capable of mixing.131  Rapid reaction times are capable within droplets due to 
their high surface area to volume ratios, their efficient heat and mass transfer, and a small 
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mean free path.92  Droplet manipulation can be automated or semi-automated by 
electrokinetic or hydrodynamic driven flow.132, 133  Droplet-based reactions are used for 
numerous chemical and biological applications, such as chemical synthesis, 
microfractionation, reaction kinetics monitoring, and particle formation, among others.134, 
135   
 
2.3.2 Droplet Formation 
To prevent inter-droplet diffusion or droplet dilution by surrounding solvent flow, 
an immiscible carrier phase is often used.  Fluorocarbon oils provide hydrophobic 
properties, which essentially eliminate diffusion of water-soluble compounds between 
droplets while causing less substrate swelling in PDMS-based microfluidic devices than 
hydrocarbon oils.136, 137  Droplets are most commonly generated via a T-junction geometry 
where a reagent channel intersects the carrier phase channel in an orthogonal arrangement, 
with droplet formation occurring at the intersection.92  Another method of droplet 
generation is flow focusing, where the carrier phase is supplied by symmetric channels 
surrounding the reagent-flowing channel.  The carrier phase flow forces the reagent phase 
flow through a constricted channel feature leading into a larger channel.  The pressure from 
the carrier phase pushes reagent through the constriction, and provides shear forces to 
separate the reagents into droplets.92  Both droplet-formation techniques (illustrated in 
Figure 2-1) can control droplet size, velocity, and frequency by adjusting flow rates, inlet 
pressures, or changing phase viscosities.  
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Figure 2-1.    Illustration of two common methods of droplet formation within microfluidic 
devices.  The use of a standard T-Junction (A) introduces the reagent fluid to the carrier fluid in 
an orthogonal manner.  When the carrier fluid flow rate is greater than that of the sum of all of 
the reagent fluids, the reagent fluids will taper off into individual droplets.  In a flow-focusing 
design (B), the carrier fluid forces the reagent fluid through a constricted feature in the channel.  
The increased pressure through the constricted feature causes sufficient shear force to form 
droplets from the reagent stream. 
 
2.3.3 Droplet Manipulation 
Analyses utilizing droplets can benefit from the ability to manipulate droplets, often 
by either division, fusion, or sorting.  Division of droplets can be completed using an 
additional T-junction, where the droplet flows to the branch point, and is stretched out by 
the extension flow.  Large enough droplets will become thin enough to split into two or 
more subsequent droplets.138  A flow-focusing technique can be used where the droplet 
flow is directed into a Y-junction, with carrier phase flow merging on both sides of the 
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droplet flow, causing droplet splitting along its length.  The size and frequency of these 
daughter droplets can be controlled by changing flow rates of the additional carrier 
phase.139    
The ability to control fusion of droplets can be a critical step in chemical or 
biological on-chip reactions.  For droplet fusion to occur, it is necessary to bring individual 
droplets into physical contact with one another in order to overcome the stabilizing effects 
provided by the carrier phase.140  Passive fusion of droplets may be achieved by 
geometrical features in the channel design.  To get droplets in close enough proximity to 
one another, the downstream droplet flow must be slowed relative to the upstream droplet 
flow.  This can be achieved by incorporating a channel feature where the dimensions are 
abruptly and briefly expanded so that trailing droplets can merge into those ahead as the 
droplet expands into the feature opening.139  Viscosity ratios of droplets and carrier fluid, 
as well as the presence of surfactant at their interface, play a significant role in droplet 
fusion.  When the droplet has a lower viscosity, the interfacial film between fluids will 
easily rupture, resulting in droplet coalescence.141  In contrast, when the droplet viscosity 
is greater, the interface becomes less mobile, increasing the difficulty of coalescence.  The 
presence of surfactant at the interface of the two phases will also inhibit fusion.89, 142 
Effective mixing within a droplet is of the upmost importance for rapid analysis 
and minimizing reaction times.  Continuous flow microfluidics exhibits laminar flow due 
to low flow rates, as well as small channel dimensions, and mixing must rely on diffusion.89  
Mixing efficiency is affected by the length of the fluid droplet or plug in which mixing is 
occurring, where longer droplet plugs are significantly less efficient in mixing than small, 
tight droplets.  Mixing efficiency is also dependent on reactant dispersion within the 
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droplet, which is heavily dependent on the method of droplet formation.90  A process 
known as chaotic advection facilitates extremely rapid mixing of reagents within droplets 
through interaction of the droplet with all walls of a microchannel.  The flow within 
droplets is continuously recirculated, resulting in shearing interactions of the droplets with 
channel walls.  This shearing process is exacerbated by droplet flow through winding 
channels and is illustrated in Figure 2-2.90, 143  
Droplet sorting is used to select specific droplets from a larger population, and their 
movement is influenced in either a serial or parallel fashion.  Necessary forces for 
movement are often based on fluidic flow, acoustic waves, or coulombic attraction and 
repulsion.92  An electrically driven technique, such as dielectrophoresis, can quickly sort 
water droplets at a frequency of over 1.6 kHz by use of microelectrodes fabricated 
underneath a PDMS microfluidic device.144  Water droplets have also been manipulated 
using a microelectrode array and alternating current voltages across the electrodes at 
frequencies ranging from 50 Hz to 1 MHz.144 
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Figure 2-2.    Process of chaotic advection within droplets in a mixing region of a microfluidic 
device.  Beginning with a droplet containing two discrete fluidic layers, the frictional forces 
induced on the droplet by the channel walls cause continuous refolding and recirculation of the 
droplet.  As mixing within droplets is primarily based on inter-layer diffusion, the multiplication 
and subsequent thinning of fluidic layers results in highly efficient mixing within droplets. 
 
2.4 Digital Microfluidics 
 Although similar to traditional microfluidics with respect to small volume analysis, 
digital microfluidics (DMF) approaches micro total analysis systems by manipulating 
individual droplets.145  These droplets move about on an open or closed chip via the 
application of electrical potentials from an array of electrodes.146, 147  Droplets are deposited 
above an array of electrodes coated with a hydrophobic insulator.  As an electrical potential 
is applied sequentially to adjacent electrodes, the droplets will move in the direction of 
applied current.  During this process, known as electrowetting, the potential applied by the 
electrode charges the surface of the insulator, making it attractive for the fluid to wet the 
surface by decreasing the droplet-surface contact angle.148, 149  This electrical manipulation 
process allowing for the automation of dispensing, transport, splitting, merging, and 
mixing of droplets.150-152  The advantage of DMF lies within its broad range of applications.  
Immunoassays were performed by the Sista group to detect insulin, interleukin-6, and 
cardiac troponin I by immobilizing the analytes using magnetic beads.153, 154  On-chip 
glucose assays have been performed for concentration analysis in whole blood, serum, 
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plasma, urine, saliva, sweat, and tears.155-157  To avoid problems such as sample 
evaporation or air contamination, droplet-based bioluminescence assays of adenosine 
triphosphate using luciferase were conducted within an immiscible oil-phase.158  Other 
enzymatic applications of DMF have investigated pre-steady-state kinetics of tyrosine 
phosphatase phosphorylation ratios using matrix assisted laser desorption ionization 
(MALDI) – time of flight (ToF) - MS and the conversion of fluorescein diphosphate to 
fluorescein by mixing droplets with alkaline phosphatase.159, 160  Deoxyribonucleic acid 
(DNA) sample handling and purification were achieved via liquid-liquid extraction from a 
mixture of DNA and proteins.161  Damaged oligonucleotides, merged with a DNA repair 
enzyme, were repaired and this repair was subsequently verified using fluorescence 
microscopy.162   
By embedding a micro-heater to facilitate thermal cycling, polymerase chain 
reaction (PCR) has been conducted on-chip with DNA amplification comparable to bench-
top methods with the added advantage of improved total analysis time and reduced sample 
consumption.153, 163, 164  The ability of DMF to individually control multiple reagents 
simultaneously makes it a beneficial system to use for proteomics.  Macroscale protein 
purification requires multiple steps, relatively large reagent volumes, and time.  Early 
DMF-proteomic applications demonstrated that six simultaneous peptide and/or protein 
samples can be purified from heterogeneous mixtures simply via sample drying and 
subsequent rinsing, followed by analysis using MALDI-ToF-MS.165-167   
For protein extraction and purification from more complex biological matrices, 
several important steps such as precipitation, rinsing, resolubilization, reduction, 
alkylation, and digestion have been incorporated on-chip.168-170    A form of “hybrid” 
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microfluidics integrates DMF with the more familiar channel microfluidics for in-line 
sample processing and separation.  Following protein purification and digestion, the sample 
can be driven by DMF to the corresponding microchannel for separation using a packed 
stationary phase or capillary electrophoresis.93  Recently, dried blood droplets have been 
used in conjunction with DMF for the quantification of amino acids.171[52] The samples 
are processed on-chip, employing similar methods to standard fluid droplets; significantly, 
this technique negates the need for centrifugation or freezing of the sample, and allows for 
simplified transportation and cataloguing. 
  
2.5 DETECTION TECHNIQUES 
 
2.5.1 Spectroscopy 
 The use of sepectroscopy, or the interaction of matter with electromagnetic 
radiation, is one of the most commonly used detection techniques with microfluidics as it 
can be sensitive and nondestructive.172   A simple absorbance detector using light-emitting 
diodes as the excitation source and optical fibers was developed for flexible integration at 
multiple device channel points for high-throughput droplet screening.135  Fourier transform 
infrared spectroscopy (FTIR) was used to image fast dynamic processes taking place within 
flowing droplets.173  Rapid scanning times of 50 ms allowed for active reaction monitoring 
within droplets.  Additional spectroscopic techniques to monitor droplet-based reactions 
were Raman and surface-enhanced Raman spectroscopy (SERS).  Kinetic studies of 
polymerization reactions within droplets were achieved using confocal Raman 
spectroscopy.174  SERS was used to provide high-speed detection for droplets containing 
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functionalized silver nanoparticle aggregates.  Characterization of these nanoparticles was 
completed with sub-millisecond time resolution.175  Although spectroscopic techniques 
such as absorbance, FTIR, and Raman typically provide high-throughput, label-free 
detection with applications for biological assays and reaction monitoring, the need for more 
highly sensitive analysis and quantification should rely on either fluorescence or MS, or a 
combination of the two. 
 
2.5.2 Fluorescence  
 Fluorescence detection can be used as either a highly sensitive and quantitative 
detection technique or a qualitative imaging detection mechanism.  Microfluidic devices 
suit both techniques well due to their high optical transparency.  Fluorescent microscopy 
often uses cameras to image fluorescing droplets and can measure single cell enzymatic 
activity.  LIF incorporates a laser as an excitation source, optical filters to minimize 
extraneous noise, and photodetectors to quantitate orthogonal fluorescence photons.    
The fluorogenic reagent, 4-methylumbeliferyl-β-η-glucuronide, was used to 
monitor enzyme activity by time-lapse fluorescence imaging of droplets.176  A custom-
designed microfluidic device detected rare, aberrant cells in a population of wild-type 
human cells through rolling circle-enhanced enzyme activity single molecule fluorescence 
detection assay.177  The high sensitivity allowed for multiplexed detection of individual 
enzymatic events at the single cell level.  A device known as “DropLab” was developed as 
a multifunctional droplet-based  microfluidic platform that provides picoliter scale droplet 
manipulation with single-cell enzyme activity detection with a fluorescence microscope.178  
A droplet microfluidic platform with fluorescence imaging setup was designed to meet 
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needs of high-throughput and high-dynamic range with multiple droplet processing 
schemes within a single chip.  The chip design incorporated PCR amplification and 
fluorescence detection and generated over one million 50 pL droplets within 2-7 minutes 
capable of simultaneous visualization and analysis.179  In other studies, a microfluidic 
device coupled with LIF was used to detect glutathione concentrations within single 
erythrocytes collected from people in different age ranges and pathological states.94  Cells 
were injected, separated, and detected on-chip, with cell population and single cell data 
simultaneously collected from electropherograms.  
 
2.5.3 Mass Spectrometry 
 While most optical detection techniques using droplet microfluidics require some 
form of chemical derivatization to analyze a reaction, MS presents the possibility of label-
free or derivatization-free analysis.  In addition to high sensitivity, MS can provide 
information about mass to charge ratios and/or structural information based on ion 
fragmentation patterns, commonly predicated by the combination of two or more mass 
analyzers.  Due to the effluent from a microfluidic chip already being in liquid form, ESI 
is a common detection choice for microfluidic analysis.  Much work has been reported on 
techniques of coupling droplet microfluidic systems to ESI-MS.96, 97, 180-182  The primary 
interfacial procedures involve either directly flowing the droplet stream into the ESI source 
or extracting the droplets into the source.  Maintaining segmented flow into the source 
allows samples to remain encapsulated until fragmentation and detection, avoiding dilution 
and sample carry-over.   
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ESI-MS has been coupled to nanoliter scale flow from segmented flow 
microfluidics to screen inhibitors for cathepsin B.97  A series of T-junctions add enzyme, 
substrate, and quenchant to an array of nanoliter droplets containing test compounds prior 
to infusion into a metal-coated, fused silica ESI emitter for MS analysis.  A direct 
segmented flow-ESI-MS analysis system was also applied for the online monitoring of a 
droplet-based micro-reaction for alkylation of peptides and to screen acetylcholinesterase 
catalyzed hydrolysis of acetylcholine.98, 181  Segmented flow was coupled to MS by 
capacitive charge transfer across the droplet-carrier phase boundary for monitoring single 
and biphasic reactions.  A spyhole drilled on top of the microchip was used to sample 
passing droplets by applying high voltage pulses from an electrode placed below the chip.  
Electrostatic-spray ionization enabled MS analysis without dilution or an oil removal step, 
surfactants, or sheath-flow.183   
MALDI has been coupled with microfluidic technology to illustrate the feasibility 
of screening methods that consume minimal quantities of substrates per reaction.  An 
optimized deacetylation reaction using only 20 µg of substrate was performed within 
segmented samples and deposited onto a plate for MALDI-MS analysis.184  A novel 
interface between droplet microfluidics and MALDI-MS enabled label-free analysis of up 
to 26,000 individual aqueous droplets on a microarray plate.  A stage containing the plate 
was synchronized with the output of droplets from the device, preventing cross-
contamination.  The system monitored the formation of angiotensin II from angiotensin I 
over a several hour enzymatic reaction.99 
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2.6 SUMMARY 
 Microfluidics has become a burgeoning field of chemical and biological sciences 
over the past two decades.  The push toward a true µTAS platform that includes sample 
preparation and handling, separations, reactions, and analysis all within a single 
microfluidic device brings about nearly limitless potential.  Increased sample throughput 
and reproducibility, reagent and sample minimization, improved reaction time and 
efficiency, and the capability of coupling highly sensitive and selective detection systems 
are what makes µTAS attractive to the modern day analyst.  Fast, easy, and cost effective 
in-house device fabrication consisting of substrate materials such as PDMS, glass, or even 
paper can be used depending on the analysis requirements.  The use of segmented flow, or 
droplet-based microfluidics allows for specialized reactions to be performed on-chip in a 
fraction of the time required on a larger scale.  Integrated microchannel features can allow 
for precise manipulation of droplets via splitting, fusion, and sorting.  While still 
technically droplet-based, digital microfluidics moves away from flow-based fluid 
handling and instead incorporates electrode-induced movement of individual droplets, 
providing an enhanced droplet manipulation ability.  Finally, microfluidics can be tailored 
to numerous detection techniques, with the most commonly used being fluorescence and 
MS.  Both techniques offer high levels of sensitivity, with fluorescence adding the ability 
of imaging-based detection and MS providing structural and mass related information. 
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Chapter 3 
CHROMATOGRAPHIC SEPARATION AND ANALYSIS 
OF PRIMARY FATTY ACID AMIDES/AMINES 
 
3.1. ABSTRACT 
 The field of lipidomics is of increasing importance as the physiological properties 
of specific lipid classes become better understood.  One such specific class of lipids, 
PFAMs, has been shown to display a myriad of signaling.  A common difficulty in analysis 
of these biological PFAMs is their presence in trace concentrations, as they are often found 
at pmol/g quantities in tissue.  Current analysis techniques, such as HPLC-MS, have 
detection limits that lie on the periphery of endogenous PFAM concentrations, making 
their quantitative analysis difficult.  The need for a more sensitive detection system, such 
as fluorescence, exists in this field, and this chapter will serve as the foundation in 
developing methodology to analyze PFAMs and their conjugate amines.. 
 Successful extraction of PFAMs from both complex lipid mixtures and biological 
tissue has been performed using either SPE or a Folch-Pi liquid-liquid extraction 
procedure.  GC-MS analysis of PFAMs presents the ability for both their identification and 
quantitation, without the need for derivatization.  To incorporate a highly sensitive 
fluorescence detection scheme into PFAM analysis, both an amide conversion and 
subsequent fluorescent tagging reaction must be employed, and is described herein. HPLC-
fluorescence detection provides the most sensitive analysis-detection scheme, with 5 fmol 
detection limits being achieved. 
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3.2. INTRODUCTION 
 Lipids are small amphiphilic bioorganic molecules that play an important role in 
several different areas of mammalian biology.  Lipids have important biochemical roles 
such as cell makeup, energy storage, essential hormones, signaling, and messenger 
functions.  As described in Chapter 1 and recent reviews, PFAMs are one specific subgroup 
of the fatty acyls lipid class that are of growing interest due to their variety of physiological 
properties.47  PFAMs are contained in the CSF of humans, cats, mice, and also within 
bovine omentum.3, 5, 185  Oleamide (C18:19), a monounsaturated PFAM, displays several 
physiological effects such as sleep induction in cats, vasodilation, and potential anti-cancer 
qualities by suppressing spontaneous metastasis in the BL6 line of melanoma cells.27, 186-
189  Anandamide (C20:54,5,8,11,14) also plays a potential role in mediating certain oleamide-
like sleep induction effects.190-192  Erucamide (C22:119) stimulates angiogenesis, as well as 
regulates fluid imbalances.35  Quantitative studies of signaling lipids can be quite difficult 
as these are found in trace concentrations in biological systems, requiring extremely 
sensitive instrumentation. The need for increasingly lower detection limits becomes 
necessary to lipidomics researchers as concentrations within samples are often at trace, 
nano- to picomolar (10-9-10-12), or even ultra-trace, sub-femtomolar (10-15), levels. 
 One method of PFAM detection utilizes fluorescence, which occurs when a 
molecule is excited at a given wavelength and then emits a photon of lower energy during 
relaxation back to the ground electronic state.  This shift in energy (which corresponds 
directly to the inverse of the wavelength) from excitation to emission is called the Stokes 
shift.193, 194  In fluorescence, the emitted photon has a longer wavelength than the excitation 
photon.195  Optimal fluorophores display large Stokes shifts due to limited structural 
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rigidity, allowing for more energy loss in the vibrational relaxation step prior to emission 
of a photon.  This increased energy loss, correlating to a large Stokes shift, results in an 
emission wavelength being significantly longer than the excitation wavelength, thus 
limiting systematic noise caused by an incident radiation source when proper optical filters 
are used in a fluorescence detection system.   
Due to the delocalization of electron density caused by the carbonyl group, amide-
reactive fluorophores are relatively non-existant, whereas amine-reactive fluorophores are 
plentiful.  In order to incorporate a fluorescence detection system into PFAM analysis, the 
PFAM must first be converted to its conjugate amine form using a modified Hoffman 
rearrangement reaction.196  Since primary fatty amines do not have a conjugated π-bonding 
system required for strong fluorescence in the UV or visible range, these molecules must 
be derivatized with a fluorophore to allow potential fluorescent detection.    The 
development of isoindole-forming derivatives such as o-phthalaldehyde (OPA) and 
naphthalene-2,3-dicarboxaldehyde (NDA) approximately three decades ago proved to be 
a critical advancement in the fluorescence analysis of amino acids and aliphatic amines.197-
199  In the presence of a nucleophile (cyanide), NDA reacts with primary amines, forming 
highly fluorescent N-2-substituted-1-cyanobenz-[f]-isoindole (CBI) derivatives.200  These 
CBI derivatives have several advantages over similar OPA derivatives, such as improved 
chemical stability, visible excitation maxima, and enhanced quantum yield.201  Wang et al. 
recently showed the potential of NDA for trace analysis of short chain aliphatic amines 
(C1-C8) using HPLC with a fluorescence detector.  Amines were extracted from an 
aqueous matrix by vortex-assisted liquid-liquid microextraction and subsequent studies 
provided  limits of detection (LOD) between 10 pM and 40 pM.200  NDA was also used to 
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fluorescently tag a series of six neuroactive amines commonly found in brain dialysate.  
Offline derivatization with NDA showed LODs for arginine, citrulline, taurine, histamine, 
glutamine, and aspartate ranging from 50 nM to 250 nM; comparable to or exceeding the 
sensitivity required for detection of these analytes within the physiological concentration 
range.202-206 
 
3.3 MATERIALS AND METHODS 
 
3.3.1 Chemicals 
 Methanol (HPLC grade), acetonitrile (HPLC grade), hexane (ACS grade), glacial 
acetic acid, ammonium hydroxide, and fluorescein isothiocyanate (FITC) were purchased 
from Fisher Scientific (Fair Lawn, NJ, USA).  Oxalyl chloride, oleic acid, erucic acid, 
petroselaidic acid, anhydrous methylene chloride, decylamine, dodecylamine, 
octadecylamine, monooleoylglycerol, phosphatidyl-choline, N-oleoglycine, and N-
oleyolethanolamine were purchased from Sigma Aldrich (St. Louis, MO, USA).  
Heptadecanoic acid, eicosanoic acid, chloroform, and diethyl ether were purchased from 
Aldrich Chemical Company (Milwaukee, WI, USA).  Lauric acid, myristic acid, palmitic 
acid, stearic acid, docosanoic acid, tetradecylamine, hexadecylamine, 
[bis(trifluoroacetoxy)iodo]benzene (PIFA), potassium cyanide (KCN), and acetone were 
purchased from Acros Organics (New Jersey, USA).  Elaidic acid was purchased from MP 
Biomedical, Inc (Solon, OH, USA).  3-(2-furoyl)quinoline-2-carboxaldehyde (FQCA) and 
NDA were purchased from Molecular Probes (Eugene, OR, USA). 
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3.3.2 Synthesis of Primary Fatty Acid Amides 
 PFAMs were synthesized in-house from their corresponding fatty acids according 
to a modified synthesis procedure originally developed for low-aliphatic amides (three to 
six carbons in length).207  Fatty acids were dissolved in methylene chloride and reacted 
with oxalyl chloride to form the acid chloride in a sealed vial under an argon atmosphere 
and constant stirring.  The reaction solvents were dried using a vacuum rotary evaporator 
at elevated temperature to reduce drying time, resulting in a colorless oily residue.  A 
syringe filled with ammonium hydroxide was inserted into the vial containing the acid 
chloride and the ammonia was allowed to slowly outgas.  The reaction was visibly 
monitored and deemed to be complete when the acid chloride turned to a white solid, 
characteristic of the PFAM form.  The final reaction product was solubilized in chloroform 
and the liquid portion was removed, dried, and stored in a desiccator.  Reaction verification 
and purity analysis were conducted using GC-MS and further detail is provided in Section 
3.3.4. 
 
3.3.3 Solid Phase Extraction and Thin Layer Chromatography 
 A method of PFAM extraction from lipid mixtures containing N18TG2 mouse 
neuroblastoma cells and bovine omentum and subsequent separation using TLC was 
originally developed by Sultana et al., and was reproduced in this work as a model for 
separation of lipid classes.61  A 3 mL polypropylene SPE tube was packed with 
approximately 500 mg of either DSC unbonded silica phase or DSC aminopropyl bonded 
silica phase between frits.  A concentrated lipid mixture containing oleamide, oleic acid, 
monooleoylglycerol, phosphatidyl-choline, N-oleoglycine, and N-oleyolethanolamine 
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were prepared and solubilized in hexane.  A 100 µL aliquot of the lipid mixture was loaded 
onto the hexane-wetted unbonded silica phase column and eluted with 1 mL each of 99:1 
(v:v) hexane:acetic acid, 90:10 hexane:ethyl acetate, 80:20 hexane:ethyl acetate, 70:30 
hexane:ethyl acetate, 2:1 chloroform:isopropanol, and 2 mL of methanol.  Fraction 6 
(containing PFAM, MAG, NAG, and NAE classes) was subsequently dried and 
reconstituted in 200 µL of hexane.  The reconstituted lipid mixture was loaded onto the 
hexane-wetted aminopropyl phase column and eluted with 2 mL each of hexane, 
chloroform, 1:50 isopropanol:chloroform, 1 mL of 1:50 isopropanol:chloroform, 3 mL of 
1:33 isopropanol:chloroform, and 2 mL of methanol.   
 To verify SPE elution of the lipid classes, each fraction from both column phases 
was spotted on 10 cm × 10 cm TLC plates and separated using a three-stage development 
process.  TLC plates were first developed to 5.5 cm in 95:5:1 chlorform:methanol:acetic 
acid and dried using a handheld dryer.  The plates were re-developed to 8 cm in 60:40:5 
hexane:diethyl ether:acetone and dried.  The plates were re-developed to 9.5 cm in 97:3 
hexane:diethyl ether and dried.  A 0.05% primuline solution was evenly sprayed onto the 
plates and dried.  The TLC plates were placed inside a UV box and viewed under 
broadband UV radiation to determine the presence of lipids in each fraction.  Spots visible 
inside the UV box were circled to allow for future analysis as visibility of the primuline-
stained spots fades with time. 
 
3.3.4 Gas Chromatography-Mass Spectrometry 
 A Varian CP-3800 GC equipped with Varian Saturn 200 ion trap MS and Varian 
CP-8400 autosampler was used for analysis of PFAMs and to also verify PFAM synthesis 
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reaction completion and assess purity.  GC separations were performed using a Varian 
Factor Four capillary column (VF-5ms).  The column stationary phase consisted of 5% 
phenyl-methyl with dimensions of 30 m × 0.25 mm ID.  Ultra-pure helium was used as the 
carrier gas with a flow rate of 1 mL/min.  The inlet temperature was set to 250°C with a 
split ratio of 10:1.  The temperature gradient began at 55°C and initially ramped to 150°C 
at 40°C/min with a 3.62 minute hold followed by a ramp to 275°C at 10°C/min with a 6.50 
minute hold, resulting in a total run time of 25 minutes.  PFAMs were ionized by either 
chemical ionization (CI) with methanol or EI ionization and analyzed using either total ion 
collection or SIM.  Varian MS Workstation version 6.9 was used for all data analysis. 
 
3.3.5 Primary Fatty Acid Amide to Amine Conversion 
 In order to conduct fluorescent labeling studies, PFAMs must first be converted to 
their conjugate amide form.  PIFA was prepared to approximately 0.15 M in a 3:1 (v/v) 
acetonitrile:water solution.  PIFA displays limited solubility, and must be extensively 
sonicated to aid in dissolution.  Using a modified conversion method originally developed 
by Feng and Johnson, approximately 20 µmol of amide was added to an amber glass vial 
with 200 µL of the PIFA reagent and the solution was sonicated for at least 60 minutes.196  
The reaction occurred overnight with the vials being kept in a dark environment.  Samples 
not used immediately following a 24 hour reaction period were stored at -4°C until future 
use. 
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3.3.6 Fluorescent Labeling of Amines 
 For optimal fluorescent tagging of amines using FQCA, 10 mM solutions of both 
FQCA and amine were prepared in methanol, and a 10 mM solution of KCN was prepared 
in water.  Optimal reaction conditions were determined to be 1:10:12 (v/v/v) equimolar 
amine:KCN:FQCA.  The reactants were mixed in an amber glass vial and allowed to react 
for approximately 45 minutes at 40°C using a heating block.  Fluorescent tagging of amines 
using NDA follows a similar procedure to that of FQCA.  Each reactant stock solution was 
prepared at 10 mM with both NDA and amine in methanol and KCN in water.  An 
equimolar 1:20:24 (v/v/v) solution of amine:KCN:NDA was required for maximum 
fluorescence intensity.  The reactants were mixed in an amber glass vial and heated at 40°C 
for approximately 30 minutes for the reaction to proceed to completion.   
 
3.3.7 Reversed Phase HPLC Separation of Primary Fatty Acid Amines 
 A Waters 1525 Binary HPLC Pump with Waters 2475 Multi Wavelength 
Fluorescence Detector and Waters Breeze version 3.30 software package was used for 
separation and fluorescence detection of amine mixtures.  A Waters Xterra MS C18 with 
5 um particle size, 3.9 mm × 150 mm column was used to separate saturated fluorescently 
tagged amine standards.  A 5 uL injection loop was used for consistent injection volumes 
and the column was maintained at room temperature.  An isocratic elution profile 
consisting of 100% methanol with a flow rate of 1.5 mL/min was used.  For analysis of 
FQCA-tagged amines, an excitation wavelength of 488 nm and an emission wavelength of 
590 nm was used with gain and energy units full scale (EUFS) settings at 100 and 1,000, 
respectively.  For analysis of NDA-tagged amines, an excitation wavelength of 405 nm and 
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emission wavelength of 470 nm was used with gain and EUFS settings at 100 and 1,000, 
respectively.  
 
3.4 RESULTS 
 
3.4.1 Solid Phase Extraction 
 A concentrated lipid mixture containing pure oleamide, oleic acid, 
monooleoylglycerol, phosphatidyl-choline, N-oleoglycine, and N-oleyolethanolamine 
standards were used to verify the SPE procedure designed to isolate lipids by class.  After 
loading the concentrated lipid mixture onto the unbonded silica phase, the PFAM, MAG, 
NAG, and NAE classes were found to elute in fraction six (methanol).  After drying, 
reconstitution, and application onto an aminopropyl phase column, PFAMs were isolated 
in fraction three (2 mL 1:50 isopropanol:chloroform) while the MAG, NAG, and NAE 
classes  elute in fraction five (3 mL 1:33 isopropanol:chloroform).  After application to and 
development on a TLC plate, a 0.05% primuline solution resulted in visible fluorescence 
of the lipids under UV light (data not shown).   
 
3.4.2 Gas Chromatography 
 GC-MS was used to separate and identify PFAMs in a mixture of mid- to long-
chain, as well as saturated and unsaturated PFAMs.  A mixture sample containing 
myristamide (C14:0), palmitamide (C16:0), stearamide (C18:0), oleamide (C18:19), and 
eicosanoamide (C20:0) were prepared at 200 µM per amide.  A 1 µL sample of the PFAM 
mixture was injected with separation occurring using a VF-5ms capillary column.  The GC 
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method conditions were sufficient for baseline resolution of all five PFAMs, inclusive of 
stearamide and oleamide, which only differ by one point of unsaturation in the aliphatic 
tail (Figure 3-1).  CI with methanol was used as the ionization source.  Fully saturated 
PFAMs with carbon chain lengths of 12, 13, 14, 16, 17, 18, 20, and 22 were individually 
run by GC-MS and their retention times were calculated versus carbon chain length.  
Consistent baseline resolution was found between peaks of fully saturated PFAMs with a 
coefficient of determination (R2) of 0.99 for retention time versus the aliphatic chain length, 
showing a linear response between retention time and chain length.   
 GC-MS was also used to verify the completion of the PFAM synthesis reaction.  
Synthesized fatty acid amides, as well as precursor fatty acids, were solubilized in 
methanol, ionized by CI with methanol, and analyzed using SIM.  The integrated peak 
areas of both the fatty acid precursor and the PFAM product were used to estimate overall 
purity, with the purity value presented as the peak area of the PFAM divided by the sum 
of the peak areas of the PFAM and residual fatty acid precursor.  All PFAMs synthesized 
were found to have 98% or greater purity. 
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Figure 3-1.    GC chromatogram showing separation of a mixture containing myristamide 
(C14:0), palmitamide (C16:0), stearamide (C18:0), oleamide (C18:19), and eicosanoamide 
(C20:0) at 200 µM per amide.  An ion trap mass spectrometer was used for detection with CI 
using methanol as the ionization source. 
  
3.4.3 Primary Fatty Acid Amide to Amine Conversion 
 As amide-reactive fluorophores are relatively non-existent, PFAMs must be 
converted into their conjugate amine form prior to fluorescent tagging.  The PIFA reaction 
occurs via a modified Hoffman rearrangement, or decarboxylation reaction, where the 
product amine contains one less aliphatic carbon than its precursor amide, and this reaction 
has been well characterized within our laboratory (Figure 3-2).  A range of mid to long 
chain saturated PFAMs consisting of dodecylamide (C12:0), tetradecylamide (C14:0), 
hexadecylamide (C16:0), and octadecylamide (C18:0) were prepared to a concentration of 
20 µM per amide individually, and equally mixed for a total amide concentration of 20 
µM.  Using a Waters Xterra MS C18 column (5 um particle size, 3.9 mm × 150 mm), the 
resulting conjugate amines were separated and fluorescently detected (Figure 3-3).  For 
preliminary PIFA conversion and verification by HPLC, FITC was used as the tagging 
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fluorophore with fluorescence detector excitation and emission wavelengths set to 495 nm 
and 520 nm, respectively.  
 
 
Figure 3-2.    Reaction scheme for the conversion of a PFAM to its conjugate amine form using 
PIFA.  The reactants undergo a decarboxylation reaction that results in the conjugate amine 
having one less carbon than its precursor amide. 
 
 
 
 
Figure 3-3.    HPLC fluorescence chromatogram showing product primary amines resulting from 
precursor PFAMs following the PIFA conversion reaction.  Converted PFAMs were injected 
independently (top four traces) and as a mixture (bottom trace).  The fluorescence response was 
acquired at excitation and emission wavelengths of 495 nm and 520 nm, respectively. 
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3.4.4 Fluorescent Tagging of Primary Fatty Acid Amines 
 In order to utilize highly sensitive fluorescence detection with ultra-trace primary 
fatty acid amine analysis, amine-tagging reactions were optimized for response and 
efficiency.  Preliminary fluorescent tagging experiments included the use of FQCA, 
however, extensive optimization of the fluorescent tagging of fatty amines focused on the 
fluorophore NDA, with further rational expanded upon in Section 3.5.  The tagging 
reaction using NDA involves both the fluorophore and the fatty amine solubilized in 
methanol in the presence of excess cyanide ion.  The basic reaction scheme is shown in 
Figure 3-4.  To determine the optimal ratio of reactants to one another, decylamine (C10:0) 
was used as the target analyte.  All reactants, inclusive of the amine, were prepared to 1 
mM and reaction mixtures were incubated at 50°C for 45 minutes to ensure reaction 
completion.  Following each reaction, the samples were diluted to an amine concentration 
of 1 µM and run in triplicate.  The average peak area of NDA-tagged decylamine was 
determined by HPLC with fluorescence detection.  Previous work using FQCA showed 
that optimal reaction conditions required an excess of NDA and KCN, therefore a reactant 
ratio of 1:10:12 (v/v/v) amine:KCN:NDA was used as the benchmark.  Additional reactant 
mixtures used ratios of 1:5:6, 1:5:12, 1:10:6, 1:1:1, and 1:20:24 (v/v/v) amine:KCN:NDA, 
with the 1:20:24 reaction resulting in the largest average peak area (Figure 3-5).   
 For optimal fluorescence detection, the fluorescence emission maximum of the 
NDA-tagged amine was determined.  Dodecylamine (C12:0) was tagged with NDA and 
diluted to an amine concentration of 1 µM and analyzed by HPLC with fluorescence 
detection.  The excitation wavelength was held at 405 nm as per the fluorophore 
manufacturer’s recommendation and the emission wavelength varied from 450 nm to 500 
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nm to determine the emission maxima, with gain and EUFS settings held constant.  
Samples were run in triplicate at each emission wavelength, with the maximum 
fluorescence response, and therefore the emission maxima, was observed at 470 nm (Figure 
3-6). 
 Each of the reactants were tested by HPLC with fluorescence detection to determine 
whether any native fluorescence may attribute to the overall fluorescence response of 
NDA-tagged amines.  Each reactant was prepared to a concentration of 100 µM and 
mixtures of two or all three reactants followed a 1:10:12 (v/v/v) amine:KCN:NDA 
equimolar ratio.  Each sample was also subjected to a 45 minute incubation time at 50°C.  
All three reactants (amine, NDA, and KCN) displayed negligible native fluorescence when 
injected independently.  Dodecylamine reacted with NDA and dodecylamine reacted with 
KCN displayed no native fluorescence.  NDA reacted with KCN did show a moderate 
fluorescence response, however, this response was dwarfed by that of the NDA tagged 
amine as shown in Figure 3-7. 
 
 
Figure 3-4.    Reaction scheme showing the fluorescent tagging of a primary fatty acid amine 
with NDA in the presence of a cyanide ion.  Optimal reaction conditions were determined with 
a reaction mixture containing 1:20:24 (v/v/v) amine:KCN:NDA in equimolar concentrations.  
The reaction takes approximately 30 minutes at 45°C to reach completion, resulting in a maximal 
fluorescence emission of 470 nm. 
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Figure 3-5.    Reaction mixtures displaying varying ratios of reactants (amine, KCN, and NDA).  
All solutions were prepared with reactants added in equimolar concentrations following the 
format of amine:KCN:NDA by volume.  Average peak area of fluorescently tagged decylamine 
diluted to a concentration of 1 µM is shown for each reaction mixture, with standard deviations 
depicted (n=3).   
 
 
Figure 3-6.    Average peak areas are shown at varying intervals of fluorescence emission 
wavelength.  Dodecylamine was fluorescently tagged with NDA and diluted to a concentration 
of 1 µM.  Fluorescence emission wavelengths ranged from 450 to 500 nm with the excitation 
wavelength held at 405 nm.  Standard deviations are shown (n=3). 
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Figure 3-7.    HPLC chromatograms showing native fluorescence of reactants and varying 
reactant mixtures.  All reactants were prepared to 100 µM and incubated at 50°C for 45 minutes.  
For mixtures, 1:10:12 (v/v/v) equimolar amine:KCN:NDA reaction conditions were used.  A. B. 
and C. show fluorescence chromatograms of NDA, KCN, and dodecylamine, respectively.  D. 
and E. show dodecylamine reacted with NDA and dodecylamine reacted with KCN, 
respectively.  F. shows the fluorescence response of KCN and NDA reacted with one another.  
G. and H. show the full reaction of NDA-tagged dodecylamine and decylamine, respectively, for 
perspective with respect to retention time. 
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3.4.5 HPLC of Primary Fatty Acid Amines 
 HPLC with fluorescence detection was used to validate the amine-tagging reaction 
and for separation of individual primary fatty acid amines from mixtures.  An NDA-tagged 
amine mixture containing decylamine, dodecylamine, tetradecylamine, and 
hexadecylamine was prepared at a concentration of 10 µM per amine using reaction 
conditions of 1:20:24 (v/v/v) amine:KCN:NDA.  Isocratic elution profiles of 100% 
methanol, 90:10 (v/v) methanol:acetonitrile, and 80:20 methanol:acetonitrile as mobile 
phases at 1 mL/min flow rates were tested to determine optimal chromatographic 
resolution.  While maintaining a 100% methanol isocratic elution profile, the flow rate was 
increased to 1.5 mL/min to determine the extent of resolution loss, which was apparent 
between decylamine and dodecylamine (Figure 3-8).  The most retained component 
(hexadecylamine) eluted within four minutes for all mobile phase compositions regardless 
of the flow rate.   
Detection limit studies were performed with an NDA-tagged amine mixture 
consisting of decylamine, dodecylamine, tetradecylamine, hexadecylamine, and 
octadecylamine.  Each amine was reacted with NDA and KCN individually, with all 
reactants prepared to 1 mM.  The reacted amines were mixed together and serially diluted 
to 1 nM per amine.  In order to achieve maximum sensitivity, the gain and EUFS settings 
on the fluorescence detector were set to 1,000 and 1, respectively.  A 5 µL injection loop 
was used, resulting in 5 fmol of each amine on-column (Figure 3-9).   
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Figure 3-8.    HPLC fluorescence chromatograms showing NDA-tagged amines (decylamine, 
dodecylamine, tetradecylamine, and octadecylamine) at varying mobile phase compositions.  All 
elution profiles were isocratic with flow rates of 1 mL/min.  A.100% methanol, B. 90:10 (v/v) 
methanol:acetonitrile, and D. 80:20 methanol:acetonitrile were used as mobile phases.  100% 
methanol was also analyzed with an increased flow rate of 1.5 mL/min (C.), which resulted in a 
loss of resolution between decylamine and dodecylamine.  
 
 
 
 
 58 
 
Figure 3-9.    An HPLC fluorescence chromatogram displaying instrumental detection limits.  A 
mixture of pre-NDA-tagged decylamine, dodecylamine, tetradecylamine, hexadecylamine, and 
octadecylamine were serially diluted to a concentration of 1 nM per amine.  A 5 µL injection 
volume resulted in the on-column load of each amine to be approximately 5 fmol. 
 
 
3.5 DISCUSSION AND CONCLUSIONS 
 The need to develop fast, accurate, and highly sensitive determination of PFAMs 
for eventual analysis of samples with trace and ultra-trace concentrations of endogenous 
PFAMs has been addressed, and this chapter serves to develop the methodology for these 
future analyses.  In order to analyze PFAMs with the sensitivity offered by fluorescence, 
the conjugate amine form must be used.  This is due to the carbonyl group on the amide 
causing a delocalization of electron density, effectively prohibiting a fluorophore from 
binding to the amide head group.  Several PFAMs were available for use as the fatty acid 
to PFAM synthesis was successfully developed and completed in-house.  GC-MS proved 
to be helpful in verifying the successful reaction completion as well as determining the 
overall percent purity of the product PFAM aided by the specificity of SIM.  GC-MS has 
the benefits of requiring no derivatization of PFAM samples and very sharp 
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chromatographic peaks due to its increased number of theoretical plates versus HPLC, 
however, detection limits range from the low µM to high nM range, with poor 
reproducibility near these concentrations.  In addition to the chromatographic benefits that 
GC offers, detection by MS enables for mass identification using either CI or EI ionization.  
CI is a soft ionization source, resulting in little or no mass fragmentation.  With analytes 
of known mass, individual peaks can be identified as the entire molecular ion will be intact 
in the mass spectrum.  In addition, SIM adds increased selectivity as any extraneous noise 
or contamination peaks can be removed from a chromatogram when the analyte mass(es) 
is/are known.  EI ionization is a much harder ionization source, with little to no molecular 
ion remaining, depending on the analyte.  This is especially useful for identification of 
unknown materials as each molecule will display a characteristic fragmentation pattern that 
can be saved to a library.  SIM may not be as useful with EI ionization unless a specific 
mass fragment is known (Figure 3-10).   
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Figure 3-10.    GC/MS spectrum comparing CI versus EI ionization of stearamide.  CI is a very 
soft ionization source (top), resulting in essentially all of the molecular ion mass remaining.  This 
ionization mode can be especially useful for identification of analytes of known mass or for SIM.  
EI is a much harder ionization source (bottom), as shown by the significant extent of 
fragmentation resulting in little to no remaining molecular ion.  This ionization mode is 
especially useful for identification of unknown components by characteristic fragmentation 
patterns that can be matched to a library database. 
 
 
 Converting a PFAM to its conjugate amine has been accomplished using PIFA, 
resulting in an amine removed of one carbon from its predecessor.  This reaction has the 
potential to be a useful tool for enabling trace and ultra-trace detection of PFAMs via 
fluorescent tagging of their conjugate amines, as none of the side-products appear to have 
a fluorescent response.  The PIFA reaction can fast become problematic, however, due to 
severe solubility issues.  PIFA is highly soluble in aqueous solutions (or at least partially 
aqueous), whereas PFAMs display little to no solubility in water, worsening as the aliphatic 
chain increases in length.  The usefulness of PIFA as a reactant to produce conjugate 
aliphatic amines of mid- to long-chain length does not appear to be realistic due to 
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solubility concerns.  Future work must explore an alternative means to conduct PFAM to 
amine conversion reactions capable of handling solubility concerns of longer chain 
aliphatic amides.   
 When dealing with primary fatty amine standards, two modes of fluorescent 
tagging have been explored.  Initial studies involved FQCA as an amine-tagging 
fluorophore, however, several drawbacks and the discovery of NDA changed the path of 
analysis.  Comparatively, NDA displays a higher quantum yield, substantially longer 
fluorescence stability, and is significantly less expensive to purchase than FQCA.  The 
NDA-amine tagging reaction was determined to produce optimal fluorescence response 
when reacted at 1:20:24 (v/v/v) equimolar ratios of amine:KCN:NDA.  This reaction was 
stable for up to two weeks with minimal fluorescence loss when stored at 4°C (unpublished 
observation).  Native reactant fluorescence studies showed that none of the reactants 
display native fluorescence alone, however a response is noticed when KCN and NDA are 
reacted with one another.  This is likely due to dimerization/oligomerization of the NDA 
molecule, however, the response is approximately ten times less than that of NDA-tagged 
decylamine and is not well retained by reversed phase HPLC, eluting prior to the earliest 
eluting of any of the amines studied.   
 Reversed phase HPLC separation of fully saturated aliphatic amines can be 
relatively easily achieved in a relatively short amount of time (less than 4 minutes for 
octadecylamine).  For ease of use, an isocratic elution of 100% methanol mobile phase can 
sufficiently separate saturated amines, however, resolution increases by slightly increasing 
the mobile phase polarity by adding 20% acetonitrile.  A more extensive gradient elution 
profile was developed by Divito and Cascio for separation of mid- to long-chain aliphatic 
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amides both fully saturated and with varying levels of unsaturation.208  A sub 2 µm particle 
size column (Agilent RP C18, 2.1 mm × 50 mm, 1.8 µm particle size) was used with a 2µL 
injection volume and a gradient elution profile beginning with a 5 minute hold of 80:20 
(v/v) methanol:water, ramp to 100 methanol over 5 minutes, and a four minute hold. 
 Fluorescence detection has the power of being a highly sensitive detection system 
for primary fatty acid amines, as evident by low fmol detection limits using an HPLC with 
fluorescence detector.  Successful conversion of PFAMs to their conjugate amines using 
PIFA is key to progressing the developed methodology of fatty acid amine analysis, 
however, inherent problems develop as chain length increases, and solubility decreases.  
NDA has shown to be a highly fluorescent fluorophore selective to amine analysis.  
Successful optimization of this tagging reaction is evident in the extremely low detection 
limits by HPLC with fluorescence detection.  As this research progresses into ultra-trace 
detection techniques, the methodology developed in this chapter serves as a strong 
foundation leading to microfluidic and LIF analysis of fluorescently tagged primary amines 
(Chapter 4). 
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Chapter 4  
DEVELOPMENT OF A MICROFLUIDIC PLATFORM FOR 
ULTRA-TRACE ANALYSIS OF PRIMARY FATTY ACID 
AMINES 
   
4.1 ABSTRACT 
 The inherent trace quantity of PFAMs found in biological systems presents 
challenges for analytical analysis and quantitation, requiring a highly sensitive detection 
system.  The use of microfluidics provides a green sample preparation and analysis 
technique through small-volume fluidic flow through micron-sized channels embedded in 
a PDMS device.  Microfluidics provides the potential of having a micro total analysis 
system where chromatographic separation, fluorescent tagging reactions, and detection 
could all be accomplished with no added sample handling.  This chapter describes the 
development and optimization of a microfluidic-LIF analysis and detection system that can 
be used for the detection of ultra-trace levels of fluorescently tagged primary fatty acid 
amines.  A PDMS microfluidic device was designed and fabricated to incorporate droplet-
based flow.  Droplet microfluidics have enabled on-chip fluorescent tagging reactions to 
be performed quickly and efficiently, with no additional sample handling.  An optimized 
LIF optical detection system provided fluorescently tagged primary fatty acid amine 
detection approaching low amol LODs.  The use of this LIF detection provides unparalleled 
sensitivity, with detection limits several orders of magnitude lower than currently 
employed LC-MS techniques. 
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4.2 INTRODUCTION 
 Initial discovery of PFAMs utilized NMR spectroscopy3; however, current work 
more commonly involves coupling GC or HPLC for separation with MS for detection and 
structural identification of endogenous or derivatized analytes.3-6, 35, 48, 61, 63, 65, 185, 191, 209-212  
MS detection, although widely employed and of great benefit, results in LODs on the 
periphery of endogenous PFAM concentrations (LOD of 10 – 400 nM depending on the 
species; Divito, unpublished), thus new methodologies for sensitive detection are required.  
The potential sensitivity of LIF makes this method an attractive alternative detection 
system.  
The use of fluorescent labeling coupled with LIF detection presents the theoretical 
ability to approach single molecule detection using a fluorophore of high quantum yield.67-
71  In the case of PFAMs, the amide must first be converted to its conjugate amine as the 
carbonyl of the amide causes delocalization of electron density, hindering the chemical 
derivatization required for fluorescent tagging at this chemical group.213  To achieve fast 
fluorescent labeling with maximal efficiency, a microfluidic platform can be utilized.  
Microfluidics is the general label given to the technology of systems that process or 
manipulate small volumes (10-9 to 10-18 L) of fluids by utilizing embedded channels with 
internal diameters on the micrometer scale and is reviewed in Chapter 2.214  Microchip 
fabrication can be performed quickly, safely, and economically via soft lithography using 
compounds such as PDMS.78  An inherent obstacle faced while performing microfluidic 
reactions on-chip is mixing efficiency, as laminar flow dominates the system at the micro-
scale due to the low Reynolds number (Re < 2300).  In laminar flow, the major form of 
mixing that occurs is diffusion between multiple streamlines, which is highly ineffective.  
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Segmented flow microfluidics presents the ability to conduct highly efficient reactions on-
chip entirely within small-volume (nL) droplets.  Droplet formation may be achieved by 
introducing at least two immiscible phases into the micro-channels via pressure-driven 
flow.  One phase consists of a carrier fluid (perfluorodecalin, gas, etc.), which is continuous 
and encapsulates the second phase (analyte and all reaction-dependent solutions) into 
segmented droplets.215  Highly efficient mixing of nanoliter-sized droplets relies on the 
repeated stretching and folding of the intra-droplet fluidic layers until these layers become 
increasingly thin to the point where inter-layer diffusion becomes even more rapid and 
efficient. 216, 217  The mixing process, known as chaotic advection, drastically reduces 
reaction time while improving reaction efficiency largely due to the significantly reduced 
mean free path as well as the absence of diffusion outside of the droplet, due to droplets 
being encapsulated by an immiscible phase.91  As the droplets flow through the micro-
channels, frictional forces introduced via contact with the channel walls causes internal 
recirculation of the droplet, enhancing mixing.  Implementing winding “S” shaped 
channels with several turns also enhances mixing by reorienting the droplet’s internal 
fluidic layers in the direction of droplet movement.91, 218, 219   
Herein, our efforts to develop a droplet-based microfluidic platform with LIF 
detection to enhance the fluorescent labeling of derivatized PFAMs and further reduce 
detection limits are described, which can be supplemented with previously developed MS 
methodology to aid in identification.208  The use of pre-chip or on-chip chromatographic 
separation, on-chip fluorescent tagging, and single photon counting detection has the 
potential to enable an in-line µTAS with detection limits sufficient for investigation of 
endogenous PFAMs.  
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4.3 MATERIALS AND METHODS 
 
4.3.1. Chemicals 
 Methanol (HPLC grade) was purchased from Fisher Scientific (Fair Lawn, NJ, 
USA).  Decylamine and dodecylamine were purchased from Sigma Aldrich (St. Louis, 
MO, USA).  Tetradecylamine, hexadecylamine, chlorotrimethylsilane, isopropanol, and 
KCN were purchased from Acros Organics (New Jersey, USA).  SU-8 2015 and SU-8 2075 
epoxy based photoresists and SU-8 developing solution were purchased from MicroChem 
(Westboro, MA, USA).  SlyGard 184 silicon elastomer kit containing base and curing 
agent was purchased from Dow Corning (Auburn, MI, USA).  NanoStrip Piranha solution 
was purchased from Cyantek (Fremont, CA, USA).  NDA was purchased from Molecular 
Probes (Eugene, OR, USA).  Perfluorodecalin was purchased from Alfa Aesar (Ward Hill, 
MA, USA).   
 
4.3.2 Microfluidic Device Fabrication 
Microfluidic device fabrication is based on the principle of photolithography with 
PDMS as the device substrate.  A 150 mm circular silicon wafer was cleaned in a NanoStrip 
Piranha solution (H2SO4 + H2O2) bath with constant agitation.  The wafer was thoroughly 
rinsed with deionized water, and dried with nitrogen.  A Laurell Technologies Corporation 
WS-650SZ-6NPP/Lite Spin Coater was used to evenly coat the wafer with either SU-8 
2015 or 2075 epoxy based photoresist.  The wafer was sealed to the spin coater rotor by 
vacuum and a constant flow of nitrogen was maintained within the 
chamber.  Approximately 4-6 mL of the photoresist was applied in the center of the wafer, 
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and evenly coated to a thickness of approximately 100 µm by the following spin coating 
method: 100 rpm/s ramp to 500 rpm, hold for 5 seconds, 300 rpm/s ramp to 2000 rpm, hold 
for 30 seconds.  The photoresist was semi-cured by heating from room temperature to 65°C 
for 5 minutes, cooled back to room temperature, heated to 95°C for 20 minutes, and cooled 
back to room temperature.  A chrome-plated photomask designed in-house using Adobe 
Illustrator software package and manufactured by Fine Line Imaging was placed over the 
photoresist-coated wafer and irradiated by high intensity broadband UV light (350-400 nm) 
using a Newport 500 W mercury-arc lamp for approximately one minute (Figure 4-
1).    The photoresist was once again cured by heating from room temperature to 65°C for 
5 minutes, cooled back to room temperature, heated to 95°C for 12 minutes, and cooled 
back to room temperature.  The unexposed photoresist was selectively removed by washing 
the wafer in an SU-8 developing solution bath with constant agitation for 10 minutes.  The 
wafer was then rinsed clean with developer, isopropanol, and finally deionized water and 
dried with nitrogen.  A PDMS solution was prepared by thoroughly mixing SlyGard 184 
silicon elastomer base and curing agent in a 10:1 (w/w) base:curing agent ratio, to a total 
mass of approximately 80 g.  The PDMS mixture was degassed using a vacuum 
desiccator.  The prepared silicon wafer was placed overtop a sheet of aluminum foil with 
the foil crimped vertically around the perimeter of the wafer, creating a boat to pour the 
PDMS mixture into.  This was placed into an oven and baked at 100°C for at least two 
hours.  Once cured, the polymeric PDMS is cut from the wafer using a razor and gently 
peeled away, taking care to not strip the photoresist from the wafer.  A detailed schematic 
of the microchip fabrication process can be found in Figure 4-1. 
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Fluidic inlet and outlet holes were bored into the PDMS microchip using a needle 
punch of the appropriate gauge to match the outer diameter of the transfer tubing that will 
be attached.  The PDMS microchip and a 25 mm × 75 mm glass microscope slide were 
thoroughly cleaned by rinsing with isopropanol and deionized water, and dried with 
nitrogen.  The microscope slide and the microchip (feature side up) were placed a Harrick 
Plasma PDC-32G plasma cleaner inside an AirClean 600 laminar flow workstation.  An 
oxygen-plasma was created within the plasma cleaner under vacuum pressure by allowing 
a slow and consistent stream of ambient air into the chamber.  Verification of plasma 
formation was made by observing a pink-purple glow from within the chamber.  The 
plasma cleaned microchip should be immediately placed (feature side down) onto the 
cleaned microscope slide and light pressure applied for several minutes to ensure a 
complete seal.  Sealing the PDMS microchip to the glass allows for a closed fluidic channel 
system.  To provide further PDMS-glass seal stability, a perimeter of quick-drying epoxy 
should be applied where the PDMS meets the glass.  Polyether ether ketone (PEEK) inlet 
and outlet tubing was inserted into the pre-bored holes on the microchip and sealed into 
place with epoxy to prevent leaking. 
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Figure 4-1.    Digital representation of a chrome-plated photomask used for PDMS microfluidic 
chip fabrication.  The photomask is placed over the photoresist-coated wafer and irradiated under 
UV light.  The channel features are transparent in the photomask, allowing for UV light to 
polymerize the photoresist underneath the mask.  This photomask allows for 12 microfluidic 
chips to be produced in a single photolithographic fabrication process.  Chip designs incorporate 
varying channel widths, which allows for differing flow rate capabilities.  For size scale, the 
diameter of the circular photomask is approximately eight inches. 
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Figure 4-2.    Schematic of PDMS microfluidic chip fabrication process using photolithography.  
An epoxy-based photoresist is spin-coated onto a clean silicon wafer (A).  A chrome-plated 
photomask is placed on top of the wafer, and is irradiated under UV light (B) to polymerize the 
exposed photoresist (C).  The wafer is washed with a developing solution to remove unexposed 
regions of photoresist (D), leaving behind a positive mold of the channel features.  A PDMS 
mixture is poured over the mold (E) and cured at 100°C.  The cured PDMS elastomer is peeled 
away from the positive mold, resulting in a microfluidic chip (F) that can be bonded to glass, 
forming a closed-channel system. 
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4.3.3 Scanning Electron Microscopy Analysis of Microfluidic Device 
 A Hitachi S-3400N scanning electron microscope (SEM) was used for analysis and 
verification of microfluidic device features.  Prior to bonding to glass, a clean microfluidic 
chip was positioned feature side up on a 15 mm aluminum sample stub affixed to a copper 
stub holder.  The high voltage was turned off and the SEM chamber was exposed to air 
prior to opening.  Once opened, the stub holder, stub, and sample were placed onto the 
specimen stage and the total height was measured to ensure no contact is made with the 
metal optics guard.  This height was inputted into the software program and the stage height 
was adjusted accordingly (sample should be approximately 1 mm from the optics guard).  
The chamber was closed and air was evacuated with a vacuum pump until internal pressure 
reached 50 Pa.  With an accelerating voltage of 15.0 kV, the sample image brought into 
focus by adjusting magnification and focus knobs on the external controller.  Brightness 
and contrast settings were also adjusted to provide the sharpest image.  Both two and three 
dimensional images of the microfluidic device were acquired. 
4.3.4. Development of a Laser Induced Fluorescence Detection System 
 For the development of a LIF detection system, all optical components were 
purchased from ThorLabs.  The excitation source was a CrystaLaser Violet Blue solid state 
laser with a wavelength of 405 nm (± 5 nm), variable power source from 0-50 mW, and 
vertical polarization.  The laser beam is reflected off of a series of mirrors and passes 
through a 405 nm bandpass excitation filter, a rotation-mounted linear polarizer set to 300°, 
and a pinhole filter.  A longpass dichroic lens with cutoff wavelength of 425 nm reflected 
incident laser light vertically through a 40x microscopic objective lens, focusing the beam 
to the desired detection region of the microfluidic device.  The resulting fluorescence 
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emission in the downward vertical plane passed back through the microscope objective and 
dichroic lens to a final mirror to reflect the fluorescence light horizontally to an optics tube.  
The optics tube contains a pinhole filter at the front end with a 472 nm emission bandpass 
filter and achromatic focusing lens within.  The fluorescence emission beam is focused 
onto the 180 µm diameter circular active area of a single photon counting module equipped 
with a silicon avalanche photodiode array detector (APD).  Individual photons generate 
transistor-transistor logic pulses, which are binned over 25 ms increments and transmitted 
to LabView data acquisition software.  A schematic of the LIF detection system can be 
found in Figure 4-3. 
 Preliminary LIF detection system alignment was conducted by visually aligning the 
excitation laser beam downstream from component to component.  Each optical component 
has alignment knobs to adjust both the horizontal and vertical angles of the component.  In 
lieu of a fluorescing sample being placed on the horizontal sample stage above the focusing 
microscope objective, a mirror was used to reflect the laser beam back to the center of the 
dichroic lens.  In order to align the optical components downstream from the second 
passing of the dichroic lens, a concentrated NDA-tagged dodecylamine solution was 
loaded into a capped, flat-sided quartz cuvette and placed on the sample stage.  The 
resonant fluorescence beam was aligned through the dichroic lens, reflected by a mirror, 
and through the optics tube.  A small, handheld dental mirror was used to ensure the 
fluorescence beam was properly focused from the optics tube onto the active area of the 
photon counting detector.  Finally, a microfluidic chip undergoing segmented flow with 
NDA-tagged dodecylamine was placed on the sample stage and the stage aligned until the 
excitation laser beam was focused directly within a sample channel.  Optical components 
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downstream from the sample stage as well as the sample stage horizontal and vertical 
alignment were adjusted until the detected fluorescence droplet response achieved the 
greatest S/N.  All alignment procedures are completed in complete darkness to allow for 
maximum excitation and emission beam visibility. 
 Several optical components required optimization to achieve the greatest possible 
S/N of NDA-tagged amine.  Signal was recorded while adjusting a pinhole filter from 
closed to its maximum diameter of approximately 2.6 mm, and precise diameters were 
measured using a caliper.  The laser polarization was adjusted from vertical to horizontal 
alignment, as well as with the rotation-mounted polarizer removed from the beam path.  
Several emission filters inclusive of 495 nm and 472 nm bandpass filters and 470 nm and 
450 nm longpass filters were tested.  Using the variable power controller, the lasing power 
was tested between 5 mW and 50 mW.  To determine variance caused by specific APDs, 
a Perkin Elmer APD was tested against two different models of EG&G APDs.  On-chip 
fluorescent tagging efficiency was examined using two different channel designs; one 
design contained a droplet mixing region containing 10 turns before the linear detection 
channel and a second design contained 130 turns before the detection channel.  A 
preliminary investigation of pre-chip chromatographic separation was conducted using a 
Dionex Ultimate 3000 HPLC Pump with a Waters Xterra MS C18 column (5µm, 3.9mm 
× 150mm).  The flow rate was held constant at 4 µL/min and a 2 µL injection volume was 
used.   
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Figure 4-3.    Schematic representation of the LIF detection system.  A 405 nm excitation laser 
beam is emitted from a solid-state laser (A) and reflected off of two mirrors (B,C).  The beam 
then passes through a 405 nm emission bandpass filter (D), rotationally-mounted polarizer (E), 
and pinhole filter (F).  The beam reflected off of a 425 nm dichroic lens (G) and focused onto 
the sample (I) using a microscope objective (H).  The resonant fluorescence beam then passes 
back through the objective and dichroic lens, is reflected off of another mirror (J), and into the 
optics tube (K) through a pinhole filter (L).  Inside of the tube is a 472 nm emission bandpass 
filter (M) and achromatic focusing lenses (N).  The focused beam is detected by a single photon 
counting APD (O). 
  
 4.3.5. Droplet Based Microfluidic Flow 
 The formation of droplet-based flow within the microfluidic device is crucial for 
conducting on-chip reactions.  To optimize droplet formation flow rates, only two inlet 
ports were used.  The inlet port with the channel that continues straight past the T-junction 
was used for the flow of perfluorodecalin, an immiscible oil-phase.  One of the three inlet 
ports with channels entering the T-junction (perpendicular to the oil-phase channel) was 
used for the flow of NDA-tagged dodecylamine (prepared according to details provided in 
Chapter 3.3.6).  Perfluorodecalin and the tagged-amine solution were loaded into separate 
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syringes and applied to the microchip using independent syringe pumps.  Flow rates were 
adjusted until rapid and consistent droplets were formed on-chip.  Droplet formation was 
detected visually due to differences in light refraction properties of perfluorodecalin and 
methanol, as well as by fluorescence detection, as described in Chapter 4.3.4.   
To conduct on-chip NDA-tagging reactions, a microchip was used with all four 
inlet ports accessible with PEEK tubing.  The oil-phase inlet was maintained as previously 
described, with the other three inlets used for the three reactants in the NDA-tagging 
reaction.  Amine, KCN, and NDA solutions were prepared at a concentration ratio of 
1:20:24, respectively, and each was loaded into a syringe.  The three reactant syringes were 
loaded onto a multi-syringe pump and all applied to the microchip simultaneously at the 
same flow rate.  Flow rates were optimized for rapid and consistent droplet formation. 
 
4.4 RESULTS 
 
4.4.1 Microfluidic Chip Fabrication and SEM Verification. 
 The use of photoresists of varying viscosities, along with programmable spin 
coating, results in precise photoresist deposition, leading to eventual channel feature depth.  
SEM can be used to precisely measure channel features, providing validation of the 
fabrication process.  Depending on the desired thickness of the photoresist substrate, either 
SU-8 2015 or SU-8 2075 epoxy-based photoresist was used.  The SU-8 2015 photoresist 
has a viscosity of 1,250 cSt while the SU-8 2075 photoresist has a viscosity of 22,000 cSt.  
This viscosity difference has a direct correlation with the thickness of photoresist coating 
at a fixed spin speed.  Spinning at 2,000 rpm results in a film thickness of approximately 
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25 µm and 100 µm for SU-8 2015 and SU-8 2075, respectively.  Three dimensional 
imagery provided by SEM allowed for the verification of the channel dimensions for a 
microchip fabricated using the SU-8 2075 photoresist, with an average channel diameter 
and depth calculated to be 155 µm and 108 µm, respectively.  Figure 4-4 shows electron 
micrographs of the inlet T-junction leading into the mixing region, a zoomed in view of 
the mixing channel, and a three dimensional image of a channel. 
 
 
Figure 4-4.    SEM imagery of channel features of a microfluidic device fabricated using SU-8 
2075 photoresist.  The four inlet channels, T-junction, and beginning of the mixing region is 
shown in a zoomed out image (A).  A zoomed in image of the mixing channel shows consistent 
curving features which allow for on-chip mixing and reactions (B).  The three dimensional image 
can be used to calculate distances between two points, enabling the determination of channel 
width and depth (C). 
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4.4.2 Optimization of Laser Induced Fluorescence Detection System 
 LIF is perhaps the most sensitive detection system known, providing sensitivity 
capabilities well below that which is necessary for the analysis of endogenous PFAMs.  
The LIF detection system required the optimization of nearly all of the adjustable optics to 
maximize S/N.  Using 1 µM NDA-tagged dodecylamine, pinhole diameters were set to 
0.762, 1.193, 1.752, and 2.641 mm and measured using a caliper.  The fluorescence 
response from each pinhole setting was captured over the course of 7-10 droplets, and all 
fluorescence chronograms were overlaid (Figure 4-5).  With the pinhole filter completely 
closed, no laser light is able to pass through, resulting in zero response.  At 0.762 mm, the 
fluorescence response is approximately 4,000 counts, while the response is approximately 
7,500 counts for each of the three larger diameter settings (Figure 4-6). 
 Using a 5 µM NDA-tagged hexadecylamine solution, the optimal laser polarization 
was determined.  With the LIF system properly aligned and recording fluorescence 
response, the polarizer was slowly rotated a full 360° to determine the position that results 
in maximum response.  At a vertical polarization of 300°, the response was at its maximum 
of approximately 15,000 counts and a S/N of nearly 380.  By completely removing the 
polarizer from the beam path, the response increased to approximately 20,000 counts with 
a S/N of 430 (Fiure 4-7).   
 Four emission filters with wavelengths at or near the emission maximum of NDA-
tagged amines were used to record fluorescence response from a 5 µM NDA-tagged 
hexadecylamine sample.  A 472x30 bandpass filter (472 nm ± 15 nm) provided the highest 
S/N at 430.  The other bandpass filter tested, 495x40 (495 nm ± 20 nm) had the worst S/N 
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at 139.  Two longpass filters were tested with a 450 nm (≥ 450 nm) and 470 nm (≥ 470 nm) 
having S/N of 305 and 226, respectively (Figure 4-8). 
 The lasing power was analyzed using a variable power controller from 5 – 50 mW.  
A 1 µM NDA-tagged dodecylamine solution and 470 nm longpass emission filter were 
used as the S/N was calculated for each power increment.  The S/N at 5, 10, 20, 30, 40, and 
50 mW power was calculated at 55.5, 98.6, 58.6, 34.6, 20.0, and 16.1, respectively.  
Extrapolation of this data and fitting to a Gaussian distribution found the S/Nmax to be at 
12.7 mW of lasing power (Figure 4-9). 
 To determine detector-to-detector variance, three APDs were used with a 10 µM 
NDA-tagged dodecylamine solution, lasing power set to 20 mW, and both 495 nm 
bandpass and 450 nm longpass emission filters.  All data recorded using the 495 nm 
bandpass filter showed a lower response than data collected using a 450 nm longpass filter.  
Both filter sets show the Perkin Elmer APD to have the highest fluorescence response, with 
the EG&G APD (large: Model SPCM-AQR-14) approximately 10,000 counts less than the 
Perkin Elmer APD (Model SPCM-AQR-14) and EG&G (small: Model SPCM-AQ-131) at 
nearly half the response of the Perkin Elmer APD using the 450 nm longpass filter (Figure 
4-10). 
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Figure 4-5.    Overlaid fluorescence chronograms showing the effect pinhole size on signal 
intensity.  With the signal intensity being zero when the pinhole is closed, it is gradually 
increased as the pinhole size is increased, eventually reaching a maximum intensity at 1.193 mm 
in diameter. 
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Figure 4-6.    Average fluorescence response shown at each pinhole diameter setting.  At a 
diameter of 0.762 mm, the average response is nearly half of that at 1.193 mm.  Further opening 
the pinhole filter past 1.193 mm does not significantly increase the average response, but, given 
the increase in the error, appears to increase the droplet-to-droplet variability (n = 7-10). 
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Figure 4-7.    Fluorescence chronogram showing the effect of laser polarization using a rotation-
mounted polarizer.  The optimal laser polarization was found to be at 300° in the vertical position, 
which is also the native polarization of the laser.  By removing the polarizer, the S/N was 
increased approximately 13%. 
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Figure 4-8.    Four different emission filters were tested to determine maximum S/N of a 5 µM 
NDA-tagged hexadecylamine solution.  The 472 nm bandpass filter showed the greatest S/N, 
with the 450 nm longpass, 470 nm longpass, and 495 nm bandpass filters showing progressive 
decreasing of the S/N.   
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Figure 4-9.    Fluorescence chronogram showing the effect on response and S/N caused by lasing 
power.  Using the variable power controller, the lasing power was set to 5, 10, 20, 30, 40, and 50 
mW and fluorescence response was recorded at each increment.  Of the individual power 
settings, 10 mW showed the highest S/N at 98.6, but extrapolation of the data fit to a Gaussian 
distribution showed the S/Nmx to be at 12.7 mW (inset). 
 
 
Figure 4-10.    Overlaid fluorescence chronograms showing the variable detector to detector 
response.  In agreement with data from Figure 4-8, fluorescence responses obtained using the 
450 nm longpass filter are greater than those using the 495 nm bandpass filter.  The Perkin Elmer 
APD was found to give the greatest fluorescence response and was used in all subsequent studies.   
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4.4.3. Droplet Formation and On-Chip Fluorescent Tagging 
 Droplet-based microfluidics presents the ability to conduct highly efficient 
fluorescent tagging reactions on-chip, minimizing additional sample handling.  For optimal 
rapid and consistent droplet formation, the flow rate of the immiscible oil phase must be 
greater than that of the reactant phase(s).  It was found that a 4 µL/min flow rate of oil 
phase to 2 µL/min flow rate of the reactant phase(s) provided the consistent droplet size 
and frequency (Figure 4-11).  It should be noted that when multiple reactants are used for 
fluorescent tagging on-chip, the summation of their individual flow rates should equal the 
2 µL/min total flow rate.  The acquisition software was set to produce a binned data point 
every 25 ms, which was sufficient to record a true maximum and minimum response for 
each droplet.   
 Detection limit studies were performed using optimized LIF detection system 
settings, a reactant flow rate of 1.5 µL/min, and NDA-tagged dodecylamine serially diluted 
to an amine concentration of 80.8 nM.  With a droplet frequency of 4.6 droplets/second, 
each droplet was calculated to contain 5.4 nL of solution.  At an amine concentration of 
80.8 nM, the average droplet contained 436 amol of fluorescently tagged amine (Figure 4-
12). 
   On-chip NDA-tagging efficiency was determined using two different channel 
designs.  A 1:20:24 (M/M/M) amine:KCN:NDA reaction concentration ratio was 
maintained with all reactants independently administered to the microchip at a flow rate of 
0.5 µL/min (1.5 µL/min total flow).  The resulting concentration of hexadecylamine per 
droplet was calculated to be 3.33 µM.  The initial chip design contained a mixing region 
with 10 turns in the channel, which resulted in incomplete fluorescent tagging as shown by 
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inconsistencies in maximum droplet response by the fluorescence chronogram (Figure 4-
13).  Transitioning to a new chip design containing 130 turns in the mixing region of the 
channel resulted in a completed fluorescent tagging reaction, as indicated by consistent 
maximum responses per droplet (Figure 4-14). 
 
 
Figure 4-11.    An example of a fluorescence chronogram showing consistent droplet formation.  
The lasing power is changed mid-acquisition with an immediate adjustment in response.  
Consistent droplet formation is determined by equal spacing between peaks (frequency) and 
equal peak widths (size).   
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Figure 4-12.    Fluorescence chronogram showing NDA-tagged decylamine approaching the 
detection limit of the LIF detection system.  The tagging reaction occurred pre-chip and the total 
amine concentration was serially diluted to 80.8 nM.  The droplet frequency was determined to 
be 4.6 droplets/second and average droplet volume was 5.4 nL/droplet, resulting in 
approximately 436 amol of amine per droplet.   
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Figure 4-13.    Fluorescence chronogram showing NDA-tagging reaction efficiency performed 
on-chip.  Reactants were maintained in a 1:20:24 amine:KCN:NDA molar ratio and applied to 
the chip independently at 0.5 µL/min.  Using a chip design with 10 turns in the mixing region 
(inset) resulted in an incomplete reaction, indicative of inconsistent maximum peak responses. 
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Figure 4-14.    Fluorescence chronogram showing NDA-tagging reaction efficiency performed 
on-chip.  Reactants were maintained in a 1:20:24 amine:KCN:NDA molar ratio and applied to 
the chip independently at 0.5 µL/min.  Using a new chip design incorporating 130 turns in the 
mixing region (inset) resulted in a completed tagging reaction, indicative of consistent maximum 
peak responses. 
 
 
4.4.4. Pre-Chip Chromatographic Separation 
 The incorporation of chromatographic separation with the development of the 
microfluidic platform described in this work is the next step towards achieving a µTAS.  
Prior to pre-chip chromatographic separations, NDA-tagged dodecylamine was prepared 
as previously described in Chapter 4.4.3 and diluted to 1 µM.  An HPLC pump was 
connected to the inlet port of the microchip, with an injection valve containing a 2 µL 
injection loop inserted into the flow path immediately preceding the chip.  A 4 µL/min 
flow rate of methanol was maintained along with a 4 µL/min flow rate of oil phase on-chip.  
Once consistent droplet flow was achieved, an injection was made without using a column 
(Figure 4-15).  NDA-tagged dodecylamine and hexadecylamine were independently 
prepared at 1 µM each for separation analysis.  A column was inserted into the flow path 
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immediately following the injection valve and preceding the chip inlet and flow rate and 
injection conditions were maintained.  Due to the poor chromatographic resolution, 
injections were made containing each tagged-amine separate from one another and the 
chromatograms were overlaid to enable easier identification of each component (Figure 4-
16). 
 
 
Figure 4-15.    Fluorescence chronogram showing unretained NDA-tagged dodecylamine.  An 
HPLC flow rate of 4 µL/minute using 100% methanol was used and a 2 µL injection was made 
immediately preceding the chip inlet.  Oil phase flow rate was held constant at 4 µL/min.  
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Figure 4-16.    Overlaid HPLC fluorescence chronograms showing separation of NDA-tagged 
dodecylamine and hexadecylamine.  An HPLC flow rate of 4 µL/minute using 100% methanol 
was used and a 2 µL injection was made with the injection valve and column immediately 
preceding the chip inlet.  The oil phase flow rate was held constant at 4 µL/min.  The 
dodecylamine and hexadecylamine are shown as red and black traces, respectively. 
 
 
4.5. DISCUSSION AND CONCLUSIONS 
The PDMS microfluidic device fabrication process using photolithography has 
numerous benefits inclusive of low cost per chip ($2 or less), relative safety (HF required 
with glass chip fabrication process), rapid fabrication (approximately 1 day), and overall 
ease of use.220  The key drawback to using PDMS is the relatively low pressure thresholds 
that induce the chip to unbond from the glass surface.  When the PDMS is oxidized by air 
plasma inside of the chamber, hydrocarbons are etched leaving behind surface silanol 
groups, resulting in a hydrophilic surface.  When placed in contact with an oxidized glass 
surface, bridged siloxane bonds are formed at the interface, creating the seal.  This seal, 
however, has the tendency to fail with increasing pressures applied to the chip from 
external syringe or HPLC pumps.  The application of an epoxy coating at the perimeter of 
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the chip and glass helps increase the pressure limits, however, there is still a tendency for 
relatively high pressures to force the fluid flowing through the channels to balloon outward, 
resulting in the chip failure and subsequent discarding. 
During the photolithographic fabrication process, it is imperative to ensure a 
perfectly cleaned silicon wafer surface prior to spin coating.  When conducting the soft 
bake process following UV exposure, the channel features will begin to faintly appear in 
the photoresist.  This is caused by the exposed region underneath of the photomask to 
polymerize in the presence of UV light, resulting in this region being less soluble in the 
subsequent developing solution.  Slight horizontal dispersion of the UV light through the 
photomask results in the channel width being slightly greater than that of the photomask.  
This is shown by the SEM micrograph having an average channel diameter of 155 µm, as 
opposed to the 150 µm width of the channels in the photomask.  
The LIF detection system requires precise alignment of all optical components in 
order to achieve fluorescence detection, with minute adjustments required for optimal S/N.  
It was determined that a greater S/N was achieved by complete removal of the rotation-
mounted polarizer.  This was somewhat expected when results showed the greatest 
response to be in a vertically polarized position, which is the native polarization of the 
incident laser.  The increase in response by removing the polarizer is due to the percent 
transmittance of the polarizer being less than 100%.  In optimizing the pinhole filter 
diameter, the fluorescence response increased as the diameter of the pinhole filter was 
increased, up to 1.193 mm, at which point no further response gain was observed.  As the 
filter was opened past 1.193 mm, a slight increase in noise was noticed while the signal 
remained constant.  The goal of the pinhole filter is to block the lower, more variable outer 
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regions of the laser beam.  A cross-sectional view of the laser beam would show a Gaussian 
distribution in laser intensity, with the center of the laser having the greatest intensity and 
the outer regions showing higher variability.  The dichroic lens displays an important 
function in that it acts as an additional filter, preventing the incident laser wavelength from 
reaching the detector.  At a 425 nm longpass cutoff, the dichroic lens reflects all light with 
a wavelength less than 425 nm (incident laser wavelength = 405 nm) and transmits all light 
with a wavelength greater than or equal to 425 nm (emission maxima = 470).  Of the four 
emission filters tested, the 472 nm bandpass filter provided the highest S/N as it falls in 
line with the optimal emission maxima of NDA-tagged amines.  A significant detector to 
detector response variability existed between the three detectors tested, with the Perkin 
Elmer APD displaying a significantly greater response as compared with the two EG&G 
APDs.  The positioning of the microchip on the sample stage is crucial to achieving a 
maximum S/N.  To prevent misalignment of the chip, it is held in place using tape, and the 
entire stage is carefully adjusted in the X, Y, and Z planes.  Optimal positioning of the 
focused laser beam should be in the center of the detection region of the channel, and the 
bottom of the glass should be within 1 mm of the focusing microscope objective.  
Meticulous vertical alignment of the stage in relation to the microscope objective is 
required while monitoring real-time fluorescence response data until the greatest signal is 
achieved. 
When optimizing flow rates for consistent droplet formation, it is necessary to have 
the immiscible oil phase be greater than that of the reactant(s) phase.  The oil phase acts as 
a carrier fluid, with the reactants combining at the T-junction and tapering off into small 
volume droplets, which are carried down-channel by the immiscible oil.  Due to the 
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extremely low flow rates and relatively long length of tubing, a significant amount of time 
is usually required for stable flow to occur, resulting in consistent droplet formation.  The 
on-chip NDA-tagging reactions shown in Figure 4-13 and Figure 4-14 illustrate the 
importance of sufficient mixing.  A linear channel exhibits laminar flow, with the only 
mixing occurring by simple inter-layer diffusion.  By introducing the turns into the channel 
design, reorientation and folding of the fluidic layers within the individual droplets is 
induced.  Each turn provides an additional fluidic layer interface, with subsequent turns 
rendering this fluidic layer infinitesimally thin to the point where simple diffusion becomes 
a fast and efficient form of mixing.  Initial chip designs incorporating 10 turns into the 
mixing region proved insufficient, as shown by the resulting fluorescence chronogram.  
The varying peak widths found in Figure 4-13 are the result of unstable droplet formation, 
not that of incomplete reaction.  The varying maximal response peak to peak shows that 
certain droplets exhibited greater reaction efficiency than others.  Additionally, broad peaks 
(indicative of sample plugs rather than droplets) such as the one at approximately 2.75 
minutes show a fluorescence response increasing within the individual droplet.  This shows 
that the reaction efficiency at the front end of the droplet was worse than the efficiency at 
the tail end.  Reaction efficiency was shown to be much improved using the modified chip 
design that incorporated 130 turns in the mixing region (Figure 4-14).  The consistent 
maximal response for each droplet indicated that the reaction was complete.   
The feasibility of conducting pre-chip HPLC separations was investigated in 
Chapter 4.4.4.  Initial injections of tagged dodecylamine were made using the smallest 
injection loop readily available (2 µL) and without a column.  In order to comply with on-
chip flow rate restrictions, a 4 µL/min flow rate from the HPLC was used.  By injecting a 
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tagged sample without a column, the degree of band broadening could be determined.  
Extreme band broadening of approximately 100 seconds was shown in Figure 4-15.  This 
is a result of a large longitudinal diffusion parameter of the van Deemter equation, which 
is exacerbated by the low flow rates and long tubing lengths between the injection valve 
and chip inlet.  Figure 4-16 shows overlaid chromatograms resulting from the addition of 
a reversed phase column positioned between the injection valve and chip inlet port.  Similar 
broadening issues exist, resulting in extremely poor resolution between a C12 and C16 
amine.   
Future work towards mitigating this band broadening issue must be addressed in 
order for the microfluidic device to provide a true µTAS.  One such method of 
improvement would be to incorporate a flow-splitting device in the flow path immediately 
following the column and before the chip inlet port.  This would enable higher, more 
traditional HPLC flow rates to be used, and necessary flow restrictions as dictated by the 
chip limitations would be incorporated by the flow-splitter.  In theory, this would minimize 
band broadening until the flow-splitter, however, preliminary experimentation using this 
setup continued to show extensive band broadening occurring due to the low flow rates in 
the tubing connecting the flow-splitter to the chip inlet.  Another option, which would 
significantly limit band broadening, would be to perform chromatographic separations on-
chip.  The modified chip design shown in the inset of Figure 4-14 shows an elongated inlet 
port, which contains a fritless weir prior to the junction point.  This weir is a horizontally 
constricted region of the channel where the width decreases from approximately 150 µm 
to 15 µm.  A slurry of reversed phase packing material with a 3 µm particle size can be 
prepared and injected into this inlet port.  As the particles enter the front of the weir, the 
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density dramatically increases causing an aggregation of particles that prevents particles 
from flowing through the weir, therefore eliminating the need for a frit.  The packing length 
can be adjusted to fill as little or as much of this inlet port as needed for optimal resolution.  
This fritless weir system of channel packing has been described in both PDMS as well as 
fused-silica capillaries.221-224  Preliminary work on packing chromatographic inlet channels 
using 3 µm particle size reversed phase packing proved difficult due to pressure restrictions 
caused by the PDMS-glass bond.  As the length of the packed column increases, additional 
back pressure is required to maintain consistent flow rates.  The fritless weir system was 
successful in stopping the flow of packing material through the column, but as the column 
length grew, the PDMS-glass bond broke, resulting in the solvent and packing material 
ballooning outward from the channel.  A more robust device substrate such as glass may 
be required to meet the pressure demands caused by flow through a packed column. 
The use of microfluidics with LIF provides the potential to detect ultra-trace 
quantities of bioactive lipids via fluorescence detection.  Detection limits using the 
previously described analysis system have shown detection capabilites at 436 amol per 
droplet (Figure 4-12).  We estimate that under these conditions, we could accurately detect 
concentrations down to 10-17 moles per droplet, which provides an improvement of up to 
three orders of magnitude over that of the currently existing HPLC-MS methodology (20 
fmol LOD).  The ability to conduct fluorescent tagging reactions and the incorporation of 
chromatographic separations on-chip enables the possibility of a true µTAS system of 
analysis, dramatically reducing any errors caused by sample handling.  Microfluidics also 
presents the opportunity to move towards a green analysis system, with a dramatic 
reduction of chemical and sample usage due to the extremely low flow rates and volumes 
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on-chip.  As LIF is a non-destructive detection technique, microfluidic device fabrication 
can be further modified to incorporate seamless integration with MS detection.  Using this 
proposed analysis system design, LIF can be used for highly sensitive quantification, while 
MS can provide accurate identification potential.  Further work towards optimizing on-
chip chromatographic separation efficiency by addressing the inherent PDMS robustness 
issues will be required prior to the investigation of using a microfluidic system for the 
analysis and highly sensitive detection of biologically endogenous PFAMs.   
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Appendix 1.  
CELECOXIB DRUG UPTAKE INTO FLUOROCARBON 
NANOEMULSIONS 
 
A.1. ABSTRACT  
The use of theranostic agents and nanotechnology has the capabilities of providing 
new platforms for disease treatments and monitoring.  Typical drug delivery vehicles 
require conjugation of a fluorescent dye to the surfactant in order to image 
biodistribution.  A theranostic nanoreagent containing a perfluorocarbon (PFC) component 
acts as both a biologically inert drug delivery vehicle as well as a magnetic resonance 
imaging (MRI) tracer capable of in vivo monitoring.  The combination of vehicle and tracer 
allows for unambiguous detection of drug delivery and its accumulation in target 
tissue.  The development of a novel theranostic nanoreagents can potentially improve the 
therapeutic function of anti-inflammatory and anti-cancer drugs.  This chapter provides 
insight to the use of HPLC-MS-MS to identify and quantitate a COX-2 inhibitor both in 
vitro and in vivo for use within theranostic nanoemulsions. 
 
A.2. INTRODUCTION 
 Theranostics, or personalized medicine, is yet another biochemical field that has 
shown marked improvements with the advancement of micro- and nano-technology.  The 
development of different systems and strategies for drug targeting to pathological sites, 
visualizing physiological processes, and the encompassing quantification has increased 
exponentially in recent years.225  The field of nanomedicine encompasses sub-micrometer 
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apparatuses used for diagnostics and treatments of disease, understanding pathophysiology 
of disease states, and improving patient quality of life.226, 227  In the case of cancer, 
traditional treatment regiments prove incredibly difficult due to molecular heterogeneity 
between cancers of the same type, between tumors and their metastatic foci, and between 
cells within an individual tumor.228  Theranostic nanomedicine, in regard to cancer 
treatment, presents the ability to diagnose, deliver targeted therapy, and monitor 
therapeutical effects.  Nanomedicine, as a whole, enable drugs to overcome chemical, 
anatomical, clinical, and physiological barriers by balancing localization in diseased-state 
versus healthy tissues and increasing accumulation at pathological sites.  This, in turn, 
increases therapeutic efficacy and reduces both the number of and intensity of side effects, 
resulting in improved patient acceptance, compliance, and prognosis.225, 229  
Specific drug targeting can come in either a passive or active form.  Passive drug 
targeting often occurs in cancer treatment, as cancerous tumors often present with leaky 
and inflamed blood vessels, allowing for extravasation of drugs and nanomaterials into the 
pathological site.225 The enhanced permeability and retention effect allows for highly 
effective and selective passive drug targeting.  In addition to having enlarged and leaking 
blood vessels, solid tumors lack functional lymphatics, resulting in the limited removal of 
nanomaterials from the drug target site.230, 231    Conversely, localization and target cell 
uptake in active drug targeting often relies on antibodies, peptides, or sugar moieties, which 
are incorporated into the nanomaterial formulation.225   
A true theranostic nanomedicine contains both therapeutics and imaging agents 
within a single nanomaterial.  The integration of diagnostics as well as therapy within a 
single nanomaterial has the potential of enabling both visualization of the material’s 
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biodistribution as well as treatment response.232, 233  A PFC nanoemulsion has been 
designed to incorporate a selective COX-2 inhibitor, celecoxib, which serves as a 
multimodal biological probe capable of studying COX-2 in macrophage tumor 
interaction.233  Additionally, the PFC nanoemulsion is equipped with dual-mode near-
infrared fluorescence and 19F MRI imaging capabilities.  The anti-inflammatory drug, 
celecoxib,  has been reported to reduce cancer risk while suppressing tumor growth.234, 235  
Additionally, celecoxib can induce COX-2 independent apoptosis, inhibit prostaglandin E2  
mediated anti-apoptic proteins, and inhibit angiogenesis.236  Celecoxib is classified as a 
class II drug and has numerous adverse properties such as poor aqueous solubility (7 
ug/mL), requiring oral administration at high doses (200-400 mg, 2x/day) which can lead 
to severe cardiovascular side effects over a several month treatment regimen.237, 238  The 
rapid elimination from plasma experienced by celecoxib lowers the actual drug levels that 
reach the pathological site, resulting in the high required dosages.239, 240  Recent work with 
celecoxib containing nanoparticles has been reported for colon cancer treatment in a human 
xenograft mouse model.240  These adverse properties displayed, and potential benefits, 
have led celecoxib to be a promising drug for use within PFC nanoemulsions.  Targeting 
circulating macrophages in and around pathological tissue sites, PFC nanoemulsions 
containing celecoxib can potentially suppress COX-2 activity while simultaneously 
allowing for the imaging of macrophage tumor infiltration dynamics.232, 233  The use of 
HPLC-MS-MS described herein provides a powerful analysis, identification, and 
quantification tool to further understand celecoxib uptake into both theranostic 
nanoemulsions as well as targeting efficiency into biological tissue. 
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A.3. MATERIALS AND METHODS 
 
A.3.1. Chemicals 
 Methanol, optima grade, and formic acid, optima grade, were purchased from 
Fisher Scientific (Fair Lawn, NJ, USA).  Methyl tert-butyl ether was purchased from Sigma 
Aldrich (St. Louis, MO). PFC nanoemulsions, celecoxib standards, and surfactant mixtures 
were provided by Dr. Jelena Janjic (Department of Pharmacy, Duquesne University, 
Pittsburgh, PA). 
 
A.3.2. Extraction of Celecoxib from Emulsion, Surfactant, and Cell Culture Matrices 
 Celecoxib was extracted from both PFC nanoemulsions and surfactant solutions for 
subsequent quantification by HPLC-QqQ-MS.  The nanoemulsions were prepared with 
1.38% Cremophor EL (CrEL) and 0.92% Pluronic P105 (P105) (w/v) and 0.188 mg/mL 
celecoxib.  The surfactant solution was prepared with 3% CrEL, 2% P105, and 1% 
dimethylsulfoxide (w/v) and 0.188 mg/mL celecoxib.  A 100 µL solution of celecoxib-
doped nanoemulsion or surfactant solution was diluted to 4.93 mL with methyl tert-butyl 
ether (MTBE).  The samples were sonicated for 3 × 10 seconds using a probe tip sonicator, 
followed by immersion in a sonicator bath for 30 minutes.  A 25 µL aliquot of the MTBE 
dilution was further diluted to 1 mL with methanol modified with 0.3% formic acid.  Both 
the nanoemulsions and surfactant solutions were diluted to celecoxib concentrations of 
200, 100, and 50 nM prior to extraction to determine percent recovery.  To eliminate any 
sample preparation or analysis bias, additional blind testing of nanoemulsions was 
conducted.  Four nanoemulsions were submitted for analysis with one containing an 
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expected celecoxib concentration of 367 µM, another containing 445 µM, and two acting 
as control samples. 
 The extraction procedure of celecoxib from macrophage cell pellets was derived 
from previous work of Vioxx extraction from cell lysate.241  Four cell pellet samples (A-
D) were submitted with pellet A containing 3.72 × 106 cells exposed to celecoxib 
containing nanoemulsion, pellet B containing 2.28 × 106 cells exposed to celecoxib 
containing nanoemulsion, pellet C containing 1.8 × 106 cells exposed to nanoemulsion in 
absence of celecoxib, and pellet D as the control containing 3.08 106 cells without exposure 
to nanoemulsion or celecoxib.  2 mL of deionized water was added to approximately 20 
µL of each cell pellet and mixed thoroughly with a micropipette to break apart the pellet.  
The solution was placed in a sonicator for approximately 30 minutes, probe-tip sonicated 
for 3 × 15 seconds, and placed back in a sonicator for an additional 30 minutes to ensure 
complete cell lysing.  Approximately 5 mL of MTBE was added to each sample and 
sonicated for 30 minutes.  The organic layer was pipetted off, transferred to a test tube, and 
dried under nitrogen gas.  The sample was resuspended in methanol modified with 0.3% 
formic acid.  Celecoxib standards were prepared and a calibration curve was created to 
allow for quantitative analysis of celecoxib extracts.  
 
A.3.3. Mass Spectrometry Analysis of Celecoxib 
 An Agilent 1200 series HPLC equipped with an Agilent 6460 QqQ-MS with APCI 
source was used for sensitive detection of celecoxib extracted from a variety of sample 
matrices.  A 6 minute isocratic elution profile was used consisting of 80% methanol and 
20% deionized water, both modified with 0.3% formic acid.  A Phenomenex C18 column 
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(4.6 × 100 mm, 2.6 µm particle size) was used with an injection volume of 15 µL and flow 
rate of 0.5 mL/min.  The MS instrumental paramaters are as follows:  fragmentor voltages 
of 135 V; dwell time of 500 ms; positive polarity; gas and vaporizer temperatures of 325 
and 350°C, respectively; gas flow of 4 L/min; nebulizer pressure of 20 psi; capillary 
voltages of 4,500 V (+) and 4,500 V (-); and corona current of 4 µA (+) and 10 µA (-).  
MRM was optimized to monitor elution of the precursor ion at 382 m/z [M+H]+ and the 
main product ion at 362 m/z with a collision energy of 30 V. 
 
A.4. RESULTS 
 Celecoxib, a COX-2 inhibitor, is of great interest in theranostic medicine for its 
anti-inflammatory and anti-cancer properties.  The HPLC-QqQ-MS methodology of 
detecting and quantifying celecoxib uptake into theranostic PFC nanoemulsions was 
developed to aid in the understanding of biological tissue targeting and therapeutic 
potential.  A standard mixture of celecoxib was prepared at varying dilution levels from 1 
– 500 nM and each sample run in triplicate to determine both linearity and reproducibility.  
Figure A-1 shows a calibration curve from the celecoxib standard data, with an R2 value of 
0.9989.  Three nanoemulsion samples and three surfactant solution samples, each of which 
containing 50, 100, and 200 nM of celecoxib, were extracted and prepared according to 
method details in Appendix 3.2, and their celecoxib concentration was determined using 
the standard curve.  Table A-1 summarizes the extraction results of celecoxib contained in 
both the nanoemulsions as well as the surfactant solutions.  A 73%, 63%, and 61% recovery 
was obtained for the 50, 100, and 200 nM nanoemulsions, respectively.  A 68%, 57%, and 
59% recovery was obtained for the 50, 100, and 200 nM surfactant solutions, respectively.  
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The data points are plotted against the standard curve in Figure A-1 to show average peak 
area at the expected concentration of each extract as compared with the corresponding 
standard. 
 A blind study consisting of two nanoemulsion standards containing 367 µM and 
445 µM and two control nanoemulsions without the presence of celecoxib were prepared 
and analyzed according to A.3.2.  A new celecoxib calibration curve was prepared with 
concentrations ranging from 1 – 500 nM for quantitation of the nanoemulsion extracts.  No 
celecoxib was detected in the two control samples.  The 367 µM emulsion was found to 
contain 235 µM in the extract, representative of a 64% recovery.  The 445 µM emulsion 
was found to contain 256 µM in the extract, representative of a 58% recovery. 
 Celecoxib concentrations were determined from the extract of four macrophage cell 
pellets, two of which were exposed to celecoxib containing nanoemulsion and two of which 
acted as controls.  A freshly prepared calibration standard was used to create a standard 
curve used for quantitation.  Pellets A and B were both exposed to celecoxib containing 
nanoemulsions and were found to contain 74.2 ng (973 nM) and 0.6 ng (8 nM) of celecoxib, 
respectively.  Pellet C was exposed to nanoemulsion without celecoxib and contained 5.5 
ng (76 nM) of celecoxib.  Pellet D was not exposed to any nanoemulsion and was found to 
contain 8.5 ng (111 nM) celecoxib. 
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Figure A-1.    Standard curve showing linearity and reproducibility of celecoxib standards run 
using HPLC-QqQ-MS.  The standards were prepared in a concentration range from 1 – 500 nM.  
The data points for each of the three nanoemulsion and surfactant solution extracts are shown 
with the concentration plotted at their expected values.  All samples were run in triplicate.  
 
 
 
 
Sample ID 
Expected Celecoxib 
Concentration (nM) 
Actual Celecoxib 
Concentration (nM) 
Celecoxib 
Recovery 
E50 50 36.6 ± 0.4 73% 
E100 100 63.4 ± 1.4 63% 
E200 200 121.5 ± 2.0 61% 
S50 50 34.0 ± 2.1 68% 
S100 100 57.4 ± 1.5 57% 
S200 200 118.0 ± 3.4 59% 
Table A-1.    Summary of celecoxib extraction from nanoemulsions and surfactant solutions.  
The expected celecoxib concentration reflects the sample preparation using known 
concentrations of celecoxib.  The actual celecoxib concentration reflects the calculated 
concentration of celecoxib extracted from each sample according to the standard curve.  The 
emulsions containing expected celecoxib concentrations of 50, 100, and 200 nM resulted in a 
percent recovery of 73%, 63%, and 61%, respectively.  The surfactant solutions containing 
expected celecoxib concentrations of 50, 100, and 200 nM resulted in percent recoveries of 68%, 
57%, and 59% respectively. All samples were run in triplicate. 
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A.5. DISCUSSION AND CONCLUSIONS 
 Instrumental parameters for highly sensitive detection of celecoxib using HPLC-
QqQ-MS were successfully developed.  The use of MRM detection allows for high 
selectivity towards the target analyte, eliminating any extraneous matrix effects.  
Fragmentation analysis from CID showed a quantitative product ion at 362 m/z, which was 
used for analysis.  A linear range of 1 – 500 nM was determined and displayed a high R2 
value of 0.9989.  The LOD for celecoxib was determined to be 15 femtomoles (1 nM).  
Celecoxib was shown to be successfully extracted from both PFC nanoemulsions as well 
as surfactant solutions, however, the measured concentration was always less than the 
expected concentration based on the amount of celecoxib added to each sample.  Several 
explanations for the rational of less than 100% extraction efficiency may exist, such as 
errors in initial nanoemulsion and surfactant solution uptake of celecoxib, surfactant 
strength effects on micelle formation, or even analyte degradation over the course of 
sample preparation, storage, and extraction.  The precise reasoning for the reported 
extraction efficiency, however, was not further pursued.  The percent recovery of celecoxib 
did appear to decrease as the expected concentration in both the nanoemulsions and 
surfactant solutions increased, potentially suggesting that the actual amount of celecoxib 
uptake into the respective samples was not as great as anticipated.  Average percent 
recoveries between nanoemulsions and surfactant solutions at the same expected 
concentration were comparable to one another.  A blind extraction study of nanoemulsions 
both containing and in absence of celecoxib showed expected results, with the two control 
samples containing no detectable amounts of celecoxib, and the two samples with drug 
having comparable percent recoveries to initial nanoemulsion extractions.  Inconsistent 
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results were noticed for the extraction of celecoxib from cell pellets.  One of the two pellets 
that was exposed to drug showed a significant amount of celecoxib (74.2 ng) in the 20 µL 
cell pellet extract, where the other pellet exposed to drug only contained 0.6 ng of celecoxib 
in the extract.  When analyzing the two control samples, the pellet exposed to 
nanoemulsions without drug contained 5.5 ng of celecoxib in the extract and the pellet 
exposed to neither nanoemulsions nor drug contained 8.5 ng.  With the second pellet 
exposed to drug displaying such a low amount of celecoxib, it can be deduced that the 
sample was either mislabeled or incorrectly prepared for the drug uptake procedure.  The 
two control samples found to contain low amounts of celecoxib show that sample 
contamination is likely of concern.  By analyzing samples using MRM, it can be confirmed 
that these two control samples did in fact contain drug, and clean blanks injected between 
each sample set show that there was no sample carry-over issues present.  Information 
pertaining to the amount of celecoxib that was added to each cell solution was not made 
available to the analyst, therefore the extraction efficiency was unknown.   
 In summary, the anti-inflammatory drug, celecoxib, is used to treat pain and 
inflammation relating to such diseases as osteoarthritis, rheumatoid arthritis, and acute 
pain, as well as show potential for reducing cancer risk by suppressing tumor growth.  The 
prospect of targeted drug delivery using nanoemulsions allows for the drug to selectively 
accumulate at the pathological site, thus increasing therapeutic efficacy and reducing both 
the number of and intensity of side effects.  PFC nanoemulsions present the prospect of not 
only a drug delivery vehicle, but also a fluorescent tracing probe that can be used to verify 
successful biodistribution using appropriate imaging techniques.  Here, we have described 
a highly sensitive and selective method of detecting celecoxib in a variety of sample 
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matrices, inclusive of surfactant solutions, nanoemulsions, and macrophage cells.  Future 
work of in vitro extraction and quantitation of celecoxib from pathological tissues, such as 
nerve cells, will be a concluding step in understanding and optimizing the uptake and 
delivery of chronic pain and anti-cancer treatments, with highly selective imaging 
techniques being used as verification. 
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